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ABSTRACT 
Head and neck squamous cell carcinoma (HNSCC) is an aggressive malignancy 
associated with molecular heterogeneity, locoregional spread, resistance to therapy and 
relapse after initial treatment. Increasing evidence suggests that master developmental 
pathways with key roles in adult tissue homeostasis, including Hippo and Wnt/β-catenin 
signaling, are dysregulated in the initiation and progression of HNSCC. However, a 
comprehensive investigation into the crosstalk between these pathways is currently 
lacking, and may prove crucial to the discovery of novel targets for HNSCC therapy. 
More recent evidence points to the tumor microenvironment, mainly comprising cancer-
associated fibroblasts (CAFs), as capable of influencing tumor cell behavior and 
promoting invasive HNSCC phenotypes. Nonetheless, current methods to screen for CAF 
markers in tumors are restricted to targeted immunostaining experiments with limited 
success and robustness across tissue types. The Cancer Genome Atlas network has 
generated multi-tiered molecular profiles for over 10,000 tumors spanning more than two 
dozen different cancer types, providing an unprecedented opportunity for the application 
and development of integrative methods aimed at the in silico interrogation of 
  viii 
experimentally-derived signatures. These multi-omic profiles further enable one to link 
genomic anomalies, including somatic mutations and DNA copy number alterations, with 
phenotypic effects driven by pathogenic pathway activity. Effectively querying this vast 
amount of information to help elucidate subsets of functionally and clinically-relevant 
oncogenic drivers, however, remains an ongoing challenge.  
To address these issues, I first investigate the effects of oncogenic pathway 
perturbation in HNSCC using experimental models coupled with in vitro genome-wide 
transcriptional profiling. Next, I describe a new computational approach for the unbiased 
identification of CAF markers in HNSCC solely using bulk tumor RNA-sequencing 
information. Lastly, I have developed Candidate Driver Analysis or CaDrA - a statistical 
framework that allows one to query genetic and epigenetic alterations for candidate 
drivers of signature activity within a given disease context.  
Collectively, this work offers new perspectives on the molecular cues underlying 
HNSCC development, while simultaneously highlighting the power of integrative 
genomics methods capable of accelerating the discovery of novel targets for cancer 
diagnosis and therapy.  
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CHAPTER ONE: INTRODUCTION 
1.1 Head and Neck Squamous Cell Carcinoma: Emerging Trends and Needs 
 Every single minute, someone somewhere in the world is diagnosed with a form 
of head and neck squamous cell carcinoma (HNSCC) - cancers that arise in the upper 
aerodigestive track mucosa. It is estimated that approximately 65,000 new cases of 
HNSCC will manifest in the U.S. alone in 2017 (American Cancer Society, 2017; 
Fitzmaurice et al., 2017; Siegel, Miller, & Jemal, 2015). The vast majority of these 
tumors (~ 90%) are presented as oral squamous cell carcinomas (OSCCs), originating 
from epithelial cells that line the oral cavity (Rosebush et al., 2011). Despite accounting 
for only 3-6% of global cancer incidences, HNSCC continues to mount a serious 
challenge to global health. Just over half of the patients diagnosed with HNSCC survive 
when followed over a five year period, a statistic that has seen negligible improvement 
over the past three decades (Haddad & Shin, 2008; Siegel et al., 2015; Warnakulasuriya, 
2009). With an annual national expenditure of around 3.6 billion dollars, HNSCC 
remains one of the most expensive cancers to treat, imposing massive financial burdens 
and drastic lifestyle changes on surviving patients (Jacobson et al., 2012). Importantly, 
HNSCC is increasingly associated with resistance to conventional therapies and 
recurrence after initial treatment, further pressing the need to discover novel and lasting 
therapeutics.  
A common trend with HNSCC is that it is diagnosed at a late stage, when 
malignant cells have spread locoregionally and may have metastasized to other tissues in 
the body via the lymphatic system. This is often attributed to complicated leading 
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symptoms, such as difficulty swallowing or loss of voice, which tend to be overlooked 
until more severe symptoms arise. While adequate public awareness and routine 
checkups can curb the number of late-stage HNSCC diagnoses, it is unlikely to alleviate 
the current lack of reliable therapeutic options. The overall poor outcomes of affected 
individuals are especially relevant given the recent progress made by the scientific and 
medical communities towards improved surgical and chemotherapeutic interventions, as 
well as in understanding the underlying molecular pathobiology of HNSCC (Grégoire, 
Langendijk, & Nuyts, 2015; Haddad & Shin, 2008; Hammerman, Neil Hayes, & Grandis, 
2015; Leemans, Braakhuis, & Brakenhoff, 2011; Rothenberg & Ellisen, 2012). Despite 
the many discoveries and inventions, however, the number of clinical trials available for 
HNSCC is approximately half that for patients diagnosed with lung or breast cancers. 
Further, no genetic tests or biomarker-based characterizations are routinely incorporated 
into current HNSCC management regimens, with patient stratification largely being 
clinical feature-based.  
 There are multiple factors that make identifying robust molecular markers for 
diagnosis and therapy of HNSCCs challenging. Most head and neck cancers are 
characterized by heterogeneity, displaying diverse anatomic, molecular and clinical 
features. Additionally, their association with independent risk factors such as human 
papillomavirus (HPV) infection, tobacco and alcohol use add further complexity to 
dissecting interactions between genetic and environmental components that can 
contribute to disease onset and progression. HPV-positive HNSCC, usually occurring in 
the oropharynx, is biologically and clinically distinct from HPV-negative HNSCC, which 
  
3 
is classically associated with tobacco and alcohol exposure. Further, patients presenting 
HPV-positive disease tend to have overall better prognosis than HPV-negative patients, 
mostly due to the fact that they are better responders to radiotherapy (Leemans et al., 
2011). Although a number of molecular alterations associated with both HPV-positive 
and HPV-negative HNSCCs have been identified, they have had limited impact on 
clinical management of this disease. These include frequent loss of tumor suppressor 
TP53, PIK3CA amplification or mutations, EGFR overexpression, and chromosomal 
instabilities leading to gain and loss of 9p and 3p chromosomal segments, respectively 
(Gross et al., 2014; Hammerman et al., 2015; Lawrence, Sougnez, Lichtenstein, 
Cibulskis, Lander, Gabriel, Getz, Yarbrough, et al., 2015). To date, few viable therapies 
exploiting these underlying biological anomalies are available for HNSCC, and only a 
small fraction of patients have benefited from these treatments. Immunotherapy, for 
example, has gathered a great deal of optimism based on early clinical success of 
inhibitors specifically targeting programmed cell death protein-1 (PD-1), a negative 
regulator of T-cell activation that is associated with immune evasion during 
carcinogenesis. While FDA-approved monoclonal antibodies nivolumab and 
pembrolizumab were shown to improve overall response rate in patients compared to 
conventional treatments, the vast majority (~75%) of total cases with recurrent or 
metastatic HNSCC remain treatment-resistant (Szturz & Vermorken, 2017).    
Thus, there exists a dire need to identify druggable targets and molecular 
mechanisms underlying the pathobiology of HNSCC in order to successfully move 
HNSCC therapy towards the emerging personalized treatment paradigm. 
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1.2 Oncogenic pathways implicated in HNSCC 
Homeostatic pathways are now increasingly known for being involved in cancer. 
These include master developmental signaling pathways such as Wnt, Hedgehog, BMP, 
TGF- Notch and Hippo signaling. Most of these pathways are evolutionarily conserved, 
and play crucial roles during both embryonic patterning, and in the maintenance of 
homeostasis in virtually every tissue and organ system of an adult organism (Clevers, 
2006; Sakata & Chen, 2011; Varelas & Wrana, 2012). These pathways are extremely 
dynamic, having the ability to be switched on and off in a matter of seconds, but also 
remain tightly regulated given their vast array of functions spanning numerous biological 
processes. Wnt signaling, in particular, plays a crucial role in daily homeostatic functions 
such as intestinal cell, hair and skin regeneration (Alonso & Fuchs, 2003), 
haematopoiesis (Malhotra & Kincade, 2009), cell migration and apoptosis. Importantly, 
aberrant Wnt signaling has been implicated in multiple cancers, including those of the 
head and neck (Zhan, Rindtorff, & Boutros, 2016; Zhou, 2010). A simplified schematic 
of this signaling cascade is shown in Illustration 1.1. Briefly, Wnt ligands are secreted 
glycoproteins that bind and activate receptor-mediated signaling within cells in 
immediate proximity. In its ‘ON’ state, binding of the ligand to a Frizzled-family receptor 
disrupts the destruction complex of -catenin (formed by axin, APC, CK1 and GSK3), 
triggering its cytoplasmic accumulation, and subsequent nuclear translocation and 
activation of the -catenin transcriptional program. This particular state, while evidently 
essential for processes surrounding tissue development and repair, is also prominent in 
cancer wherein -catenin signaling is dysregulated and remains constitutively active.  
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HNSCC is further associated with subpopulations of cells that exhibit stem cell-
like properties, or cancer stem cells (CSCs), that are also characterized by elevated 
Wnt/-catenin activity. These CSCs have the ability to resist standard therapy and seed 
new tumors at low numbers, conferring properties of recurrence and locoregional spread 
in aggressive HNSCCs (Holland, Klaus, Garratt, & Birchmeier, 2013; Reya & Clevers, 
2005; Visvader & Lindeman, 2012). The potential for Wnt signaling modulators to 
eliminate these drug-resistant and tumor-initiating cancer stem cells through promoting 
cellular differentiation, thereby sensitizing resistant tumors to conventional therapy, is a 
particularly appealing strategy. Several inhibitors of this pathway have been proposed in 
the last decade, although many were accompanied by negative side effects when used for 
the treatment of human patients, and none have been approved. Safe modulators of this 
pathway capable of abolishing aggressive cancer phenotypes remain to be discovered 
(Kahn, 2014). One potential solution to this ongoing challenge is presented in this thesis 
dissertation. 
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Illustration 1.1 Schematic representation of Wnt/-catenin signaling cascade 
Left: In normal adult tissue, Wnt, a secreted ligand protein and initiator of this signaling pathway, is absent, leading to 
the recruitment of a phosphorylation/destruction complex (blue) which ultimately binds and degrades cytoplasmic -
catenin – the main co-activator and mediator of nuclear Wnt signaling activity (green). Right: In response to tissue 
injury or activation of the repair program (induced by the presence of malignant lesions), Wnt is secreted by 
neighboring cells leading to the displacement of the destruction complex and the subsequent accumulation of 
cytoplasmic -catenin. This results in an increased nuclear translocation of -catenin, where it can bind specific co-
activators (CBP, p300; purple) or directly activate transcription factors (TCF; blue), in turn driving the transcription of 
genes involved in several processes, including cell proliferation and survival. 
 
Another signaling pathway with pivotal tumor suppressive roles is the Hippo 
pathway, that mediates the activities of key transcriptional co-activators YAP and TAZ 
(YAP/TAZ) (Harvey, Zhang, & Thomas, 2013). Similar to the oncogenic Wnt/-catenin 
pathway, transcriptional activities of YAP/TAZ rely on their recruitment to the nucleus, 
thus promoting binding to a range of transcription factors, and enhancing cell 
proliferation, survival and migratory signals (Camargo et al., 2007; Moroishi, Hansen, & 
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Guan, 2015; Varelas, 2014). Several studies have shown that Wnt/-catenin signaling 
influences and shares multiple effectors and regulatory mechanisms with YAP/TAZ 
signaling (Azzolin et al., 2014; Park et al., 2015; B. P. Tsai, Hoverter, & Waterman, 
2012). Additionally, epidermal growth factor receptor (EGFR) activity is a well-
established regulator of cell proliferation and survival, influencing the development of 
many cancers, including HNSCC. Indeed, application of EGFR-specific antibodies, such 
as cetuximab, have proved a successful treatment strategy for a small subset of HNSCC 
patients, especially when combined with radiotherapy (Leemans et al., 2011).  
Despite the established involvement of these pathways in HNSCC development, 
assessing the overlap in downstream effectors as a consequence of inhibiting oncogenic 
YAP/TAZ-, EGFR- or nuclear -catenin-mediated transcriptional activity is unclear. This 
would be essential for dissecting the impact of existing treatments capable of targeting an 
interacting pathway ‘network’ of oncogenic effectors all at once, and is crucial to the 
discovery of novel targets for lasting HNSCC therapy.  
1.3 The Tumor Microenvironment and Carcinoma-associated Fibroblasts 
 Tumors are often perceived as ‘organs’ as opposed to self-contained masses of 
aberrantly proliferating cells (D Hanahan & Weinberg, 2000). Tumor cells interact with 
their surrounding microenvironment in a reciprocal manner to favor progress towards 
advanced disease, coupled with the inhibition of the host immune system - a well-
established hallmark of cancer (Douglas Hanahan & Weinberg, 2011). This intercellular 
communication within the tumor microenvironment (TME) is complex, and is driven by 
a network of cytokines, chemokines, growth factors and matrix remodeling enzymes, 
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capable of physically and chemically altering tissue properties, including cellular 
stiffness and polarity (Augsten, 2014). The TME comprises a host of different cell types, 
including fibroblasts – cells embedded within connective tissue that are known for 
synthesizing collagen, the primary component of the extra-cellular matrix (ECM). While 
fibroblasts are quiescent in normal tissue, their ability to become activated, synthetic 
myofibroblasts is a well-known phenomenon, and has been shown in processes including 
wound healing, tissue fibrosis and cancer (Darby, Laverdet, Bonté, & Desmoulière, 2014; 
Desmoulière, Darby, & Gabbiani, 2003; Gabbiani, Ryan, & Majno, 1971). Activated 
fibroblasts show enhanced ECM production, cytoskeletal rearrangements in addition to 
gaining contractile properties. Under normal circumstances, this acquired synthetic 
function is reversible, wherein the activated fibroblasts are either rewired to become inert 
or undergo apoptosis once the repair process is finished. Cancer-associated fibroblasts 
(CAFs), however, continue to exhibit enhanced secretory phenotypes regulated in an 
autocrine fashion, with specialized ECM remodeling and immunomodulatory signaling 
abilities (Illustration 1.2). 
 
 
 
  
9 
  
Illustration 1.2 The biology and functions of fibroblasts in wound healing and cancer 
Fibroblasts are spindle-shaped cells that normally exist in an inert quiescent state. Under stress, injury or specific 
stimuli, they become activated as normal activated fibroblasts (NAF) and are characterized by enhanced collagen 
secretion and extra-cellular matrix remodeling abilities. Under normal circumstances, this process is reversible and 
naturally withdraws as soon as the injury is repaired, with NAFs undergoing apoptosis or dynamic cellular 
reprograming. In the case of persistent stimulus, like in the presence of malignant lesions or fibrosis, these cells gain 
specialized and irreversible enhancements, including immunomodulatory signaling functions, observed in cancer- or 
fibrosis-associated fibroblasts (CAFs and FAFs), with these cells further enabling disease progression. Adapted from 
Kalluri R. The biology and function of fibroblasts in cancer (Kalluri, 2016). 
 
CAFs indeed form the largest fraction of the TME cellular niche, with their 
hyperactivity affecting the behavior of malignancies of several tissue origins (Barron & 
Rowley, 2012; Kalluri, 2016). Unchecked CAF activity is thus an important and 
prominent target for aiding diagnosis and therapy. Existing CAF markers are neither 
consistent in their expression across tissue types, nor are they specific to fibroblast cell 
types (Kalluri & Zeisberg, 2006). While the application of single-cell sequencing 
techniques to further characterize tumor expression landscapes is gaining popularity, it 
presents new challenges in delineating the vast array of cell types captured, and tends to 
rely on using previously identified markers for this purpose. Further, experimental 
techniques attempting to characterize markers that track with fibroblast activity in 
cancers are often restricted to targeted immunostaining experiments based on previous 
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studies, with limited reproducibility across tissue types. Thus, being able to identify such 
markers from bulk tumor expression data using unbiased, computational approaches can 
prove useful for discovering novel and robust CAF markers spanning multiple tissue 
contexts.    
1.4 Multi-omic investigations: Applications for HNSCC and beyond  
Large-scale genomic surveys are increasingly expanding our understanding of 
important molecular cues that drive disease phenotypes. At the transcriptional level, 
curated pathway annotations and gene sets including canonical and hallmark pathway 
member annotations, transcription factor targets and chemical perturbation gene 
signatures are obtainable via the molecular signature database (MSigDB)(Liberzon et al., 
2015). MSigDB alone houses over 10,000 gene expression signatures since its creation, 
enabling gene set-based querying approaches such as gene set enrichment analysis 
(GSEA) and gene set projection (GSP). Specifically, GSP algorithms have made it 
possible to overlay the deluge of human RNASeq and gene expression profiling data with 
in vitro-based gene expression signatures of interest, allowing one to ask targeted 
questions about their biological and clinical relevance within the assessed context. This 
dissertation exploits this approach, utilizing signatures pertaining to oncogenic pathway 
perturbation either from chemical treatment or effector knockdown in HNSCC cells.  
In addition to these signature querying capabilities, large collaborative efforts 
such as The Cancer Genome Atlas (TCGA) (Chang et al., 2013) and the Cancer Cell Line 
Encyclopedia (CCLE) (J Barretina et al., 2012) have accumulated multi-omic genomic 
data pertaining to thousands of primary tumor samples and cell lines, respectively, 
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spanning many cancer types (Fig. 1.1). These include microarray gene expression 
profiling, RNA-sequencing (RNASeq), somatic mutation and copy number alteration 
calls, DNA methylation and protein expression profiling (Table 1.1). For HNSCC alone, 
TCGA has data for over 500 tumors with paired clinical information (Table 1.2). 
Consistent with globally-observed trends, majority of TCGA HNSCC samples present as 
OSCCs, and are HPV negative (Fig. 1.2A). Notably, OSCC patients have an overall 
worse prognosis compared to those with tumors arising at alternative anatomic sites (Fig. 
1.2B). The in vitro signatures and experimental assays described in this thesis are mostly 
derived using HSC-3 and CAL27 cells which are metastatic and non-metastatic human 
oral tongue tumor-derived cell lines, respectively. Thus, the TCGA OSCC cohort is 
representative of the general afflicted population, with the corresponding genomic 
profiles serving as a reasonable reference when projecting human data onto the generated 
in vitro signatures of interest. 
 Given this wealth of information, the TCGA network has published several 
‘flagship’ studies where they comprehensively characterized the genomic landscape of 
cohorts spanning multiple cancer contexts. These analyses are immensely powerful in 
identifying frequently occurring aberrations, including somatic mutations and 
chromosomal copy gains and losses, shedding light on underlying biological mechanisms 
that might be shared or unique to these cancers. Further, they are helpful in suggesting 
potential strategies for targeted therapy moving forward (Chang et al., 2013; Lawrence, 
Sougnez, Lichtenstein, Cibulskis, Lander, Gabriel, Getz, Pham, et al., 2015). Numerous 
other studies have emerged that either solely rely on these large, public datasets to either 
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make novel discoveries through rigorous statistical investigations, or to use them as 
proxies of experimental model systems. Thus, these repositories serve as a tremendous 
resource for both data querying and method development, in turn aiding in the generation 
of novel hypotheses and findings. This thesis specifically delves into the development 
and application of new statistical frameworks that enable targeted querying capabilities, 
allowing one to prioritize features associated with oncogenic activity for future follow-up 
studies. 
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Table 1.1 Multi-omic profiling information available as part of TCGA and CCLE projects  
Resource TCGA CCLE 
Total samples 
profiled* 
14,551 1,457 
Number of primary 
site types¥ 
29 40 
Microarray gene 
expression  
 
RNASeq  
CNA Profiling  
Mutation calls  
Protein expression   X 
DNA Methylation  
Pharmacological 
profiling 
X 
 
* Corresponds to the total number of primary site samples (TCGA) or cell lines (CCLE) for which at least one profiling 
dataset exists. 
¥ Corresponds to the total number of tissue site types covered within each project compendium.  
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Table 1.2 TCGA HNSCC cohort sample distributions based on clinical features  
Clinical Attribute Category Sample size 
Tissue Type 
AN 44 
Tumor 522 
Gender 
Male 415 
Female 151 
Tumor Grade 
Grade 1 63  
Grade 2 305 
Grade 3 125 
Grade 4 7 
Grade N/A 18 
HPV status 
Positive 104 
Negative 460 
Indeterminate 2 
Neoplasm anatomic subtype 
Alveolar Ridge* 18 
Base of Tongue* 29 
Buccal Mucosa* 22 
Floor of Mouth* 66 
Hard Palate 7 
Hypopharynx 10 
Larynx 128 
Lip 3 
Oral Cavity* 87 
Oral Tongue* 143 
Oropharynx 9 
Tonsil 44 
 
All entries pertain to the superset for which RNASeq profiling was performed (2015/11/01 Firehose release; n=566). 
AN: Adjacent Normal. * indicates OSCC anatomic subtypes. 
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Figure 1.1 Number of cases profiled as part of CCLE and TCGA projects 
Data obtained from https://portal.gdc.cancer.gov/ and https://portals.broadinstitute.org/ccle for TCGA and CCLE, 
respectively. Number of cases is based on the number of cell lines or primary tumors that have at least one whole-
genome profiling method performed in CCLE and TCGA, respectively.   
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Figure 1.2 TCGA HNSCC sample distribution and patient survival statistics. 
A. Distribution of samples in the TCGA HNSCC cohort with respect to anatomic subtype and HPV status. 
Subtypes qualifying as OSCCs are highlighted in purple, with others shown in green B. Kaplan-Meier 
curve based on overall survival (OS) for TCGA HNSCC patients. Patients were grouped as either OSCC or 
other HNSCC anatomic subtypes, and their OS estimates compared. P-value is based on a log-rank test.     
  
17 
1.5 Dissertation Aims 
The demand for better diagnosis, prognosis, treatment and clinical management of 
these cancers obligates a better understanding of the underlying pathobiology implicated 
in HNSCC. In this thesis dissertation, I present a series of studies that combine 
computational genomics analyses and experimental profiling and validation strategies, 
together with novel method development for context-specific genomic data interrogation. 
The subsequent chapters feature three major studies, each involving the following 
broader aims:  
Aim 1: Characterize the transcriptional effects of small molecule treatment in 
HNSCC 
Master developmental pathways, including Wnt and Hippo, are well-known 
regulators of cell renewal, differentiation and survival and their dysregulation has been 
shown to be implicated in multiple cancers, including those of the head and neck 
(Castilho & Gutkind, 2014; Hiemer et al., 2015; Nusse & Clevers, 2017; Zanconato, 
Cordenonsi, & Piccolo, 2016). Developing small molecules that can safely target these 
oncogenic pathway effectors has been a challenging task due, in part, due to negative side 
effects that result from treatment, giving them the title of ‘chemical Jekyll and Hydes’ 
(Sakata & Chen, 2011). A comprehensive investigation into the effects of targeting 
branches of these pathways and their network of effectors that are implicated in HNSCC 
is currently lacking, yet such studies are crucial to the discovery of novel and lasting 
therapeutics. To address this issue, I characterize the effects of modulating -catenin/Wnt 
pathway activity using a preclinical molecule ICG-001 that specifically targets the 
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interaction between -catenin and its binding partner CREB-binding protein (CBP), in 
turn inhibiting nuclear -catenin/CBP activity. First, I generate and annotate ICG-001 
treatment-associated gene signatures for both malignant, as well as non-metastatic 
HNSCC cell lines based on gene expression profiling using Microarrays. I will show how 
ICG-001 impacts expression of genes influencing important molecular processes 
associated with an epithelial state. I will then show that ICG-001 abrogates aggressive 
properties of HNSCC in vivo using animal models, and how this aligns with the 
phenotypes observed in vitro. Lastly, by overlaying TCGA OSCC RNASeq and patient 
data on the derived in vitro signatures, I will highlight the clinical relevance of targeting 
this pathway network. 
 
Aim 2: Identify markers of cancer-associated fibroblasts in OSCC using bulk tumor 
gene expression profiling  
 The tumor microenvironment (TME) comprises a complex and dynamic cellular 
milieu, of which carcinoma-associated fibroblasts (CAFs) form a major part (Kalluri, 
2016). CAFs possess the ability to self-promote enhanced ECM production and 
remodeling properties, making them important markers for cancer diagnosis, and for 
alternative targets for cancer therapy. Identifying such markers has been a real challenge 
given the dynamic nature and plasticity of these cells (Kalluri & Zeisberg, 2006). Current 
fibroblast markers are either not expressed in all fibroblast subtypes, or are expressed in 
both fibroblasts and other non-fibroblast cells, making them neither reliable nor specific 
across tissue types (Kalluri & Zeisberg, 2006). To address this issue, I will first show that 
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the expression profile of a ‘meta-gene’ feature comprising the major collagens produced 
by fibroblasts is a robust surrogate marker for stromal activity in OSCC. Using RNASeq 
data from TCGA, I will then demonstrate how this reference can be used to identify 
candidate CAF markers in an unbiased, genome-wide manner based on gene co-
expression with the collagen meta-gene expression (termed as a ‘nearest-neighbor’ 
analysis), with a discussion of the relevance of the top hits. Importantly, I will show how 
we validate some of these hits experimentally, including specific receptor proteins, to be 
CAF-specific makers in OSCC specimens via immunohistochemical- and 
immufluorescence-based assays. Finally, I will extend this computational approach to 
other cancers profiled in the TCGA to obtain a ‘pan-cancer’ set of core CAF markers that 
are shared between cancers of various tissue origins. 
 
Aim 3:  Developing a statistical framework that allows for the identification of 
candidate drivers of signature activity using ranked binary genomic features 
 Recent advances in high-throughput technology have led to a rapid rise in the 
generation of multi-omic data at unprecedented levels. Data portals that are part of the 
TCGA and CCLE networks, as well as the cBioPortal (Gao et al., 2013) contain state-of-
the-art query tools making the wealth of data highly accessible and interpretable. While 
these are useful for interrogating observational sample data including gene and protein 
expression, DNA copy number and somatic mutation calls, they do not allow for the 
identification of a clinically- or functionally-relevant subset of molecular features that are 
associated with a signature of interest. Importantly, a user-friendly, flexible 
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computational framework that enables one to achieve the same is currently lacking. To 
this end, I present Candidate Driver Analysis (CaDrA) – a new R package that enables a 
stepwise heuristic search for epi(genetic) features that are associated with a provided 
signature-based sample ranking. After summarizing the algorithms core functionality and 
package features, I will demonstrate its application to simulated data to estimate the 
overall sensitivity and specificity to real-scale genomic datasets. I will then apply CaDrA 
to real genomic data from CCLE and drug sensitivity profiles to highlight the ability of 
CaDrA to recover known oncogenic drivers in characterized cell lines. Lastly, I show 
how CaDrA can be used to identify novel drivers of oncogenic pathway activity in 
primary human tumors, with experimental validation of the same.    
 
In the following chapters describing these studies, I will use “we” in cases where 
experiments or functional validation was performed by collaborators that offer either 
support or additional insight to the investigations being described, and first person (“I”) 
to describe work that I specifically conducted myself. Further, each chapter in this thesis 
dissertation has been adapted from manuscripts also prepared for publication as original 
research articles that are currently accessible (Kartha et al., 2016, 2017).  
 
Collectively, this dissertation seeks to expand our understanding of the 
mechanisms surrounding HNSCC development in the context of malignant cells and their 
surrounding microenvironment, and to concomitantly highlight the power of leveraging 
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high-throughput datasets and novel integrative genomics search methodologies to further 
accelerate new hypothesis generation in oncology research.  
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CHAPTER TWO: FUNCTIONAL CHARACTERIZATION OF ONCOGENIC 
DRIVERS IN OSCC 
2.1 Background 
The Wnt/-catenin pathway is an evolutionarily-conserved, and tightly-regulated 
signaling cascade that plays pivotal roles in development, tissue injury and regeneration, 
hematopoiesis and maintenance of somatic stem cell niches in multiple tissue types (Lien 
& Fuchs, 2014; Nusse & Clevers, 2017; Wend, Holland, Ziebold, & Birchmeier, 2010). 
Under normal conditions of development and homeostasis, the transcriptional activity of 
-catenin is subject to negative regulatory controls (Brembeck, Rosário, & Birchmeier, 
2006; Zhan et al., 2016). In contrast, persistent activation of -catenin signaling due to 
somatic inactivating mutations in the upstream regulatory components of the Wnt 
pathway, or as a result of activating mutations in the -catenin gene, CTNNB1, can 
contribute to the development of many cancers, including HNSCC (Castilho & Gutkind, 
2014; Zhou, 2010) (Illustration 1.1). Targeting -catenin nuclear activity, however, has 
not been extensively explored for the treatment of this malignancy. 
Recent findings suggest that Wnt/-catenin signaling contributes to advanced 
HNSCC disease and resistance to current therapies (Castilho & Gutkind, 2014; Zhou, 
2010). In addition to activating the expression of genes with tumor promoting activities, 
Wnt/-catenin signaling has been shown to promote aggressive cancer phenotypes 
through the maintenance of cancer stem cells (CSCs). CSCs exhibit the ability to self-
renew, are capable of seeding tumors at low numbers in mouse xenografts and driving 
tumor progression to invasion and metastasis. These CSCs are highly resistant to 
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conventional therapies and are believed to be linked to cancer cell expansion, 
locoregional spread with lymph node metastasis, and tumor recurrence following 
treatment (Holland et al., 2013; Shiozawa, Nie, Pienta, Morgan, & Taichman, 2013; 
Song, Chang, Chen, Kang, & Wang, 2010; Visvader & Lindeman, 2012). Recently, CSCs 
with increased -catenin transcriptional activity were identified in HNSCC (Wend et al., 
2013). Thus, targeting β-catenin in OSCC has the potential to inhibit and eliminate 
treatment-resistant CSCs, thereby intercepting this malignancy. 
The important roles played by Wnt/-catenin signaling in cancers prompted the 
development of targeted agents, including several protein and small molecule inhibitors 
which have displayed modest efficacy in vivo (Anastas & Moon, 2013; Kahn, 2014; 
Voronkov & Krauss, 2013). Initially, these inhibitors targeted primarily upstream 
components of the Wnt/-catenin pathway and were accompanied by deleterious 
functional consequences. In contrast, blocking nuclear -catenin activity that specifically 
impacts its transcriptional targets has demonstrated more promise. Of particular interest is 
a small molecule inhibitor that preferentially blocks the interaction between -catenin 
and cAMP-response element-binding (CREB)-binding protein (CBP) in the nucleus 
(Emami et al., 2004). First identified for its anti-tumorigenic effects in pre-clinical 
models of colorectal cancer (Emami et al., 2004), ICG-001 has been shown to have a 
beneficial role in interfering with multiple diseases (Arensman et al., 2014; Grigson et al., 
2015; Sasaki, Hwang, Nguyen, Kloner, & Kahn, 2013; Stiles, 2011). Nonetheless, little is 
known about the molecular and cellular mechanisms targeted by ICG-001 in HNSCC.  
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The following study combines functional and computational approaches to 
specifically explore the molecular and transcriptional effects, as well as the clinical 
relevance of ICG-001 treatment in HNSCC.  
  
  
25 
2.2 Methods 
2.2.1 Cell lines and EC50 measurements 
Cell lines were obtained from the following sources: human CAL27, SCC9, and SCC25 
cells were purchased from ATCC, and human HSC-3 cells were obtained from 
XenoTech, Japan. All cell lines were authenticated by short tandem repeat DNA profiling 
every 6 months either by ATCC or Genetica, with last validation in October, 2016. Cells 
were grown at 37oC under 5% CO2 to 70% confluence in DMEM (Invitrogen) 
supplemented with 10% fetal bovine serum, penicillin, and streptomycin, as described 
(Liu et al., 2013). Determination of EC50 in response to ICG-001 treatment at different 
concentrations of the drug was carried out using IncuCyte live-cell imaging per 
manufacturer’s instructions (Essen BioScience). Briefly, OSCC cells were grown in T75 
flasks, collected by trypsin digestion and washed in 5-10 ml DMEM media containing 
10% FCS. Cells were seeded in Essen Bioscience 96 well Image Lock plate (Bioscience 
96 well ImageLock Microplate #4379) at a density of 2000-3000 cells/well and allowed 
to attach for 12-24 hours. Next, cells were treated with different concentrations of ICG-
001 (Selleckchem): 0.1, 0.3, 1, 3, 10, 20 and 30 µM and examined at 6-hour time 
intervals. After 72 hours, data were transferred to the Excel format and analyzed using 
the GraphPad Prism program. 
2.2.2 Nude mice and orthotopic xenograft experiments 
All experiments were approved by the Boston University Medical Center Institutional 
Animal Care and Use Committee.  HSC-3 cells were lentivirally transduced with DsRed 
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and suspended in serum-free Dulbecco’s modified eagle medium (DMEM). For 
orthotopic tongue xenografts, 0.5 × 106 cells in 40 l of DMEM were injected into each 
tongue of two-month old nude mice (Taconic Farms, Hudson, NY) that were anesthetized 
with isoflurane. Anesthesia was administered in an induction chamber with 2.5% 
isoflurane in 100% oxygen at a flow rate of 1 L/min and then maintained with a 1.5% 
mixture at 0.5 L/min. Two days following injection, mice (n=16) were equally divided 
into two groups: vehicle (DMSO control) and ICG-001-treated. For tumor inhibition 
studies, ICG-001 was diluted in 0.1% DMSO and administered via oral gavage at a 
concentration of 80 mg/kg into treatment-group mice via the tongue daily. Digital caliper 
measurements were performed at 2 – 3 day intervals to monitor the volumes of all 
tumors. Mice were imaged for DsRed protein expression on day 17 using an IVIS 200 
system (Xenogen, Alameda, CA, USA). The fluorescence signals were optimized for the 
DsRed protein at excitation 570 and emission 620. Fluorescence region of interest (ROI) 
data were calibrated and normalized fluorescence efficiency (p/s/cm2/sr)/(μW/cm2) 
determined as per the instructions (Perkin Elmer, USA). The data are reported as 
normalized fluorescence intensity (FU) from a defined region of interest for oral tongue 
tumors or systemic metastases compared to control vehicle-injected mice. Mice were 
sacrificed at day 20 and tumors were harvested and processed for further analyses. 
2.2.3 Mouse tumor sample processing 
Tumors were harvested at sacrifice at day 20, weighed and either snap-frozen and 
processed for histology, immunohistochemistry and immunoblot analyses. Tumors were 
paraffin-embedded and 5 µm sections were placed on Fisherbrand Superfrost Plus 
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Microscope Slides (Fisher Scientific), deparaffinized, treated with Retrievit-6 Target 
Retrieval Solution (BioGenex), and processed for immunofluorescence and histological 
analyses (see below). Frozen tumor tissues were used for immunoblot analyses. 
2.2.4 Immunofluorescence and immunoblot analyses 
Morphologies of OSCC cell lines comprising CAL27, HSC-3, SCC9 and SCC25 cells 
treated with ICG-001 or DMSO vehicle control were examined using a Nikon Eclipse 
TE300 microscope. For indirect immunofluorescence analyses, cells were grown to 70% 
confluence on Nunc Lab-Tek II Chamber Slide (Thermo Fisher Scientific), fixed in 3.7% 
paraformaldehyde, permeabilized with 0.1% Triton X-100, blocked with 10% goat 
serum, and incubated with primary antibodies to -catenin (Abcam, rabbit polyclonal AB 
followed by secondary antibody, goat anti-rabbit conjugated with Alexa Fluor 488 
(Jackson ImmunoResearch). Sections were counterstained for nuclei with 4'6-diamidino-
2-phenylindole, dihydrochloride (DAPI) (Molecular Probes), mounted in ProLong Gold 
Antifade, (Molecular Probes) and images were analyzed with a Zeiss LSM 710-Live Duo 
Scan confocal microscope.  The observed changes in cellular phenotypes in response to 
the ICG-001 treatment were quantified using two independent criteria: cell size (area 
occupied by cell; n=15) and junctional organization of -catenin at the membrane (width 
of membrane localization; n=10). All images were quantified using the ImageJ software. 
Mouse tumor tissue sections were blocked with 10% goat serum, mouse IgG blocking 
reagent (Vector) and incubated with antibodies against -catenin, E-cadherin (Abcam, 
rabbit) and vimentin (Sigma, mouse) followed by secondary antibodies, goat anti-rabbit 
and goat anti-mouse conjugated with Alexa Fluor 488. Negative controls lacked primary 
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antibodies. The slides were mounted in ProLong Gold Antifade and optical sections (0.5 
µm intervals) were analyzed by confocal microscopy using a Zeiss LSM710-Live Due 
Scan confocal microscope. To compare fluorescence intensities between samples, 
settings were fixed to the most highly-stained sample with all other images acquired at 
those settings. Images were processed with ZEN 2 and ImageJ imaging software. 
  Total tissue lysate (TTL) from harvested mouse orthotopic tongue tumors was prepared 
by grinding tumors to a fine powder in liquid nitrogen, and extracting total tissue proteins 
with Triton/β-octylglucoside buffer. Protein concentrations for TTL were determined 
using BCA assay (Pierce). For immunoblot analyses, TTL (20-30 g of total protein) 
were fractionated on 7.5% SDS-PAGE, transferred onto polyvinylidene difluoride 
membranes, blocked with 5% nonfat dry milk, and incubated with primary antibodies to 
either E-cadherin or -catenin (Abcam, rabbit) and GAPDH (Novus Biologicals). 
Protein-specific detection was carried out with horseradish peroxidase-labeled secondary 
antibodies conjugated to horseradish peroxidase (Bio Rad), and Enhanced 
Chemiluminescence Plus (Amersham Biosciences). Signal intensities were normalized to 
GAPDH (Novus Biologicals). 
2.2.5 Histology 
Mouse tumor tissues were fixed overnight in 4% paraformaldehyde in PBS and 
dehydrated. Samples were embedded in paraffin and sectioned (5-m thickness) and 
stained with hematoxylin and eosin (H&E) at the Boston University Medical Campus 
Pathology Core Facility. Digital images of stained slides were acquired with a TE 300 
microscope (Nikon). Quantification of the effects of ICG-001 on tumor spread in 
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harvested tongue tumors was carried out by measuring tumor area (region occupied by 
cancer cells) relative to the total section on the slide. 
2.2.6 Microarray gene expression profiling and analysis 
Three separate wells (triplicate) from 6 well plates were seeded by HSC-3 and CAL27 
cells (around 5x104/ well). After 12-24 hours (i.e. approximately 50% confluency), the 
cells were treated with either 0.1% DMSO or 10 µM ICG-001. After 48-64 hours, the 
cells were trypsinized and harvested for RNA purification using miRNeasy Micro Kit 
(QIAGEN #217084). Gene expression profiling was performed in triplicates per 
treatment group (n=3) using Affymetrix Human Gene 2.0ST arrays. Raw expression 
values were normalized together using the Robust Multiarray Average (RMA) with the 
affy R package. A BrainArray Chip Definition File (CDF) was used to map the probes on 
the array to unique Entrez Gene identifiers 
(http://brainarray.mbni.med.umich.edu/Brainarray/Database/CustomCDF). Differential 
gene expression analysis with respect to ICG-001 treatment was performed for each cell 
line using the Limma R package v3.14.4 (Ritchie et al., 2015). Filtered false discovery 
rate (FDR) q-values were recomputed based on the Benjamini-Hochberg method 
(Benjamini & Hochberg, 1995) after removing genes that were not expressed above the 
array-wise median value of at least one array. Only genes with absolute linear fold-
change > 1.5 and filtered FDR q < 0.01 were considered and used for further analysis as 
the ICG-001 treatment signature. 
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2.2.7 Gene set enrichment analysis (GSEA) 
GSEA v2.2.1 desktop software was used to perform enrichment analysis on the derived 
ICG-001 treatment profiles (Subramanian et al., 2005). Pre-ranked GSEA was run for the 
β-catenin and YAP/TAZ knockdown (KD) in HSC-3 cells, using the t-statistic of 
microarray differential expression results comparing siRNA to CTNNB1 or YAP/TAZ 
versus scrambled siRNA control conditions for β-catenin and YAP/TAZ KD, 
respectively, as the continuous ranking variable (n=23,744 and 23,466 ranked reference 
genes for siCTNNB1 and siYAP/TAZ, respectively). Gene sets pertaining to ICG-001 
treatment in HSC-3 cells were derived as described above, and were queried for 
enrichment within the ranked β-catenin and YAP/TAZ KD reference. YAP/TAZ KD 
microarray data was generated and analyzed as previously described (Hiemer et al., 
2015). All default parameters of the GSEA software were used. 
2.2.8 TCGA data processing and analysis 
RNA-sequencing (RNASeq) expression and matched clinical data pertaining to The 
Cancer Genome Atlas (TCGA) OSCC samples (n=352) was obtained and processed as 
previously described (Kartha et al., 2016). TCGA RNASeq data was projected in the 
space of the set of genes down-regulated by ICG-001 in both HSC-3 and CAL27 cells 
(n=104) using ASSIGN (Shen et al., 2015), yielding sample stratification based on the 
coordinated level of ICG-001-down-regulated gene expression (measured by ICG-001-
inhibition ASSIGN scores). Only samples with known tumor grade information were 
retained when comparing scores with respect to tumor grade. Survival analysis was 
performed using the survival package in R (https://cran.r-project.org/). Patient survival 
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information pertaining to the February 4th 2015 Firehose release was used to compute 
overall survival for TCGA OSCC patients. Patients were divided into two groups (ICG-
001-high and -low) based on the median ASSIGN scores pertaining to ICG-001 
inhibition. AE and metastatic tumor samples were filtered out for this analysis (i.e. only 
the primary tumor-associated ASSIGN scores were used to bin samples into ICG-001 
high, and low groups). Analysis of scores with respect to tumor grade was done using a 
pairwise one-sided t-test between adjacent grade groups (g2 vs g1, g3 vs g2 and g4 vs 
g3), with their corresponding p-values combined as previously described (Dai, Leeder, & 
Cui, 2014). 
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2.3 Results 
2.3.1 Inhibition of β-catenin/CBP-mediated transcriptional activity interferes with OSCC 
cell growth and drives membrane localization of β-catenin in vitro 
The small molecule inhibitor, ICG-001, has been shown to inhibit the interaction 
between -catenin and CBP in the nucleus and to affect transcription of a subset of -
catenin target genes (Emami et al., 2004; Ma, Nguyen, Lee, & Kahn, 2005). We first 
verified the inhibitory effect of ICG-001 on transcriptional activity of -catenin using the 
TOPflash-driven Renilla luciferase reporter assay (Fig. S.1). Given that intrinsic nuclear 
activity of β-catenin has been associated with treatment-resistant features of carcinomas, 
we examined whether ICG-001would impact phenotypes of OSCC cells. Thus, we 
examined -catenin localization in response to ICG-001 in a panel of cell lines including 
CAL27, HSC-3, SCC9 and SCC25 cells using immunofluorescence staining and high-
resolution confocal microscopy. Remarkably, while vehicle-treated cells displayed a 
broad distribution of -catenin at the cell membrane, ICG-001 promoted a more focused 
localization of -catenin in all four cell lines evaluated (Fig. 2.1A). This was 
accompanied by a more compact epithelial cell phenotype, as indicated by reduced 
average cell size (Fig. 2.1B). Additionally, examination of junctional β-catenin by 
immunofluorescence imaging in Fig. 2.1A revealed tighter organization as indicated by 
its diminished thickness at the membrane, a feature that accompanies more mature 
cadherin junctions (Fig. 2.1C). These results conclude that treatment with ICG-001 
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promoted junctional organization of -catenin in OSCC cells and enhanced their 
epithelial morphology.  
  We then determined the in vitro sensitivity of the four OSCC cell lines to ICG-001 
using incuCyte live imaging. Dose-dependent inhibition of cell growth was observed for 
all cell lines examined following 72 hours of treatment with ICG-001, with EC50 values 
of 2.3 µM, 2.8 µM, 5.4 µM and 8.3 µM for HSC-3, SCC25, SCC9, and CAL27 cells, 
respectively (Fig. 2.1D). Notably, the metastatic cell lines were more sensitive to ICG-
001 compared to the non-metastatic CAL27 cells (Fig. 2.1D). Subsequent analyses 
focused on CAL27 and HSC-3 cells to represent non-metastatic and metastatic 
phenotypes, respectively. 
2.3.2 ICG-001 impacts expression of genes involved in Wnt signaling, cell proliferation, 
survival and intercellular adhesion 
To determine the effects of disrupting β-catenin/CBP-mediated activity with ICG-
001 in OSCC cell lines, we performed gene expression profiling of RNA isolated from 
CAL27 and HSC-3 cells treated with either vehicle (DMSO) control or ICG-001 using 
microarrays. Differential gene expression testing between ICG-001 treatment and control 
groups yielded cell type-specific ICG-001 treatment signatures (Fig. 2.2A). Consistent 
with EC50 values in vitro, which demonstrated greater ICG-001 treatment sensitivity of 
HSC-3 cells as compared to CAL27, HSC-3 cells showed a greater transcriptional 
response to treatment (1,390 up-regulated and 1,238 down-regulated genes) than CAL27 
cells (246 up-regulated and 256 down-regulated genes) (Fig. 2.2B). Importantly, genes 
known to be targets of Wnt/β-catenin signaling (DKK1, WNT5B, CCND2, CDK1, LEF1, 
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and SKP2) and to play a role in cell survival and proliferation (BIRC5, CCNE1, CCNE2, 
CCNB1, CCNB2, CDKN3 and CDCA7) were significantly down-regulated, while genes 
with key roles in intercellular adhesion (CLDN1, CLDN4, CLDN9, CLDN16, CDH4 and 
ICAM1) were up-regulated, with greater effect in HSC-3 cells than in CAL27 cells (Fig. 
2.2C and Fig. 2.3A). Of significance, cell markers that were previously identified to be 
associated with a more stem cell-like state in HNSCC (DNAJC6, NR5A2, HELLS, KRT5 
and KRT14), and characterized by elevated β-catenin activity (Alam, Sehgal, Kundu, 
Dalal, & Vaidya, 2011; Wend et al., 2013), were also found to be significantly down-
regulated by ICG-001 in HSC-3 cells (Fig. 2.2C and Fig. 2.3A). Treatment effects of 
ICG-001 on selected genes within these functional groups in CAL27 and HSC-3 cells 
were confirmed using quantitative real-time PCR (Fig. 2.3B). These results further 
support the observed phenotypic effects of ICG-001 (Fig. 2.1A-D).   
2.3.3 ICG-001 treatment correlates with inhibition of oncogenic pathway activity 
   We previously highlighted the oncogenic role associated with the activity of key Hippo 
signaling co-activators YAP and TAZ in OSCC progression to aggressive phenotypes 
(Hiemer et al., 2015).  To assess whether ICG-001 treatment correlated with knockdown 
of β-catenin or YAP/TAZ in vitro, we tested by Gene Set Enrichment Analysis (GSEA) 
the derived ICG-001 treatment signatures against a gene list ranked by the differential 
expression of either β-catenin or YAP/TAZ siRNA knockdown versus a scrambled 
control in HSC-3 cells. We observed a significant positive correlation between ICG-001 
treatment and β-catenin or YAP/TAZ knockdown (FDR q < 0.001), confirming that ICG-
001 treatment indeed targets specific downstream β-catenin and YAP/TAZ-mediated 
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transcriptional activity in aggressive OSCC cells (Fig. 2.4). To further evaluate whether 
ICG-001 treatment exhibits shared or contrasting transcriptional effects compared to 
existing annotated treatment signatures, we turned to the Connectivity Map (CMap) 
(Lamb, 2006), a dataset housing over 476,000 cellular expression signatures pertaining to 
chemical and genetic perturbation experiments for nearly 28,000 perturbagens. CMap 
queries for the set of genes in the HSC-3 treatment signature suggested that ICG-001 
mimics treatment with EGFR and MAPK inhibitors (Fig. 2.5A), while antagonizing 
effects observed with overexpression of cell cycle regulator cyclin D1 and inhibition of 
NFkB (Fig. 2.5B). 
2.3.4 ICG-001 inhibits OSCC tumor growth and aggressive phenotypes in vivo 
Previous studies have shown that while CAL27 cells form orthotopic tongue 
tumors in nude mice, these tumors do not metastasize to distant sites. In contrast, HSC-3 
cell-driven tumors undergo significant metastases in nude mice (Bais, Kukuruzinska, & 
Trackman, 2015). To determine whether ICG-001 treatment impacted growth and 
metastasis of HSC-3 xenografts, we treated mice (n=16) with either ICG-001 (n=8) or 
DMSO vehicle (n=8) by oral gavage beginning on day three following cell implantation 
into the tongues of nude mice, with treatment repeated every day. For these studies, cells 
were transduced with red fluorescent protein (DsRed) to track tumor growth and 
metastasis prior to orthotopic inoculation. Primary tumor growth was monitored every 
two to three days using caliper measurements. In addition, in vivo imaging system (IVIS) 
was used to follow localization of DsRed-expressing cells. Comparison of relative 
radiance efficiencies at day 17 post-inoculation revealed significantly-reduced primary 
  
36 
tumor growth (P = 4.65e-3, two-tailed t-test) and whole body metastases (P = 0.013, two-
tailed t-test) associated radiance intensities in the treated versus control groups (Fig. 
2.6A). Further, starting at 13 days post-inoculation, we observed a significant reduction 
in tumor volume (P < 0.005, two-tailed t-test) following treatment with ICG-001, relative 
to vehicle treated-control mice (Fig. 2.6B). Histological hematoxylin and eosin (H&E) 
analysis of vehicle-treated tumors revealed streaks of invasive cells growing out from 
primary tumors into the tongue stroma, while ICG-001-treated tumors displayed a 
capsular phenotype (Fig. 2.6C). Quantification of the tumor cross-sectional area taken up 
by squamous carcinoma cells was significantly reduced relative to the control condition 
(P = 0.005, two-tailed t-test; Fig. 2.6C). Interestingly, examination of E-cadherin protein 
levels by immunoblot revealed that ICG-001 treated tumors exhibited increased E-
cadherin abundance compared to vehicle control-treated tumors (P = 0.016, two-tailed t-
test), while levels of -catenin were not significantly altered (P = 0.67, two-tailed t-test; 
Fig. 2.6D). Immunofluorescence analyses of these tumors showed that the ICG-001-
treated tumors phenocopied ICG-001-treated OSCC cell lines in vitro and displayed 
robust E-cadherin and -catenin junctional localization with an almost complete loss of a 
mesenchymal protein vimentin, further indicating that ICG-001 promoted an epithelial 
phenotype (Fig. 2.6E). 
2.3.5 ICG-001 treatment signature is associated with tumor progression and patient 
survival in primary human OSCC 
To align the activity of genes repressed by ICG-001 with clinically aggressive 
OSCC, we assessed the derived ICG-001-inhibited gene expression profile in primary 
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human OSCC samples by querying RNA-sequencing (RNASeq) data from the cancer 
genome atlas (TCGA). Specifically, the TCGA OSCC sample cohort (n=352) was 
projected onto the set of transcripts significantly down-regulated with treatment in both 
CAL27 and HSC-3 cells using the ASSIGN framework (Shen et al., 2015), thus capturing 
shared inhibitory activity over broader OSCC phenotypes. Samples were scored based on 
the coordinated expression of the gene signature, with a high (low) score corresponding 
to coordinated up- (down-) regulation of the signature genes, which in turn, reflected the 
level of potential ICG-001 inhibition (hereafter referred to as the ICG-001 inhibition 
score) per sample (Fig. 2.7A). The expectation was that samples with high inhibition 
score (i.e. with coordinated up-regulation of the signature genes) would be more 
responsive to ICG-001 treatment. Thus, we tested whether ICG-001 inhibition scores 
were predictive of patient outcome, as measured by the overall survival (OS) estimates 
for OSCC patients (n=318). Comparison of the survival curves corresponding to patients 
with high (> median) or low (≤ median) ICG-001 inhibition scores showed a significantly 
lower OS in the former group (Fig. 2.7B; P = 0.0063, log-rank test), with median survival 
estimates of 2.7 and 5.48 years in the high and low groups, respectively. This confirmed 
that the ICG-001 inhibition signature was predictive of patient prognosis in OSCC and 
suggested that patients with high inhibition scores were likely to be responsive to the 
treatment targeting -catenin/CBP activity. Furthermore, comparison of the ICG-001 
inhibition scores in OSCCs (n=320) versus normal adjacent epithelial (AE) samples 
(n=32) yielded significantly higher scores in OSCCs than in AE’s (Fig. 2.7C; P < 0.0001, 
two-tailed t-test), thus showing that ICG-001 inhibition was associated with tumor status. 
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We then assessed samples with known tumor grade information (n=311) to determine the 
association between ICG-001 inhibition scores and tumor progression. Remarkably, ICG-
001 inhibition scores were found to significantly increase with advanced tumor grade 
(Fig. 2.7D; combined P < 0.0001), suggesting a correlation with tumor progression. 
Taken together, these results show that higher inhibition scores in primary tissues are 
associated with tumor status and positively associated with tumor progression, and 
suggest that more aggressive/advanced tumors would be more responsive/susceptible to 
inhibition by ICG-001.  
 
2.4 Discussion 
The role of Wnt/-catenin signaling in cancer has been acknowledged for several 
decades, although its precise contributions to cancer biology remain only partly 
understood (Zhan et al., 2016). In addition to serving as a major mediator of canonical 
Wnt signals and a structural component of cadherin junctions, -catenin plays critical 
roles in a plethora of cellular functions such as cytoskeletal dynamics, cell division and as 
a regulator of apoptosis (MacDonald, Tamai, & He, 2009). Because of these complex 
functions in homeostasis and tissue renewal, targeting -catenin has been controversial. 
Most recent studies have highlighted the importance of inhibiting the nuclear function of 
-catenin downstream of the Axin/GSK3 destruction complex, thus intercepting its 
oncogenic nuclear activities while allowing it to participate in different homeostatic 
processes (Kahn, 2014; Qu et al., 2016). In this chapter, we show that a small molecule 
inhibitor of nuclear -catenin-CBP interaction, ICG-001, abolishes OSCC cell 
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proliferation and drives an epithelial phenotype, in part, by promoting membrane 
localization of -catenin without affecting -catenin transcript or protein levels. ICG-001 
treatment had most pronounced effect on metastatic HSC-3 cells suggesting that they 
were more dependent on the -catenin/CBP activity compared to non-metastatic CAL27 
cells. In mouse models of tongue OSCC, ICG-001 inhibits invasive tumor growth and 
promotes a capsular phenotype. ICG-001 treatment-specific gene expression profiling 
further highlighted the role of -catenin/CBP signaling in cell proliferation, survival, 
adhesion and stemness. Notably, I also show that the coordinated activity/expression 
level of ICG-001-inhibited transcripts stratifies primary tissue samples by their prognosis 
and identifies patients likely to respond to the inhibitor.  Collectively, these results 
suggest that OSCC cells, and aggressive OSCC cells in particular, rely on -catenin/CBP 
activity and that targeting this activity offers promise for OSCC therapy.    
The interplay between Wnt/-catenin signaling and E-cadherin adhesion has been 
shown to regulate the epithelial phenotype by affecting cell polarity, cytoskeletal 
dynamics and epithelial-to-mesenchymal transition (Heuberger & Birchmeier, 2010). As 
a structural component of E-cadherin junctions, -catenin plays key roles in intercellular 
adhesion. In response to ICG-001 treatment, the OSCC cell lines and orthotopic murine 
xenografts displayed enhanced β-catenin localization at the cell membrane coincident 
with increased E-cadherin abundance and junctional localization. Similar effect of ICG-
001 was also detected in a murine tumor immunocompetent model (data not shown), 
providing evidence that ICG-001 inhibits aggressive properties in SCC irrespective of the 
immune microenvironment (Nelson & Nusse, 2004).  
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These studies also reveal that ICG-001 gene signatures derived from differential 
gene expression testing were cell type-specific with a significantly larger number of 
changes found in more aggressive HSC-3 cells than in non-invasive CAL27 cells. One 
possible explanation is that aggressive HSC-3 cells utilize more cellular processes that 
depend on the -catenin/CBP axis activity than non-metastatic CAL27 cells. Indeed, due 
to its acetyltransferase function, -catenin-recruited CBP promotes open chromatin 
structure by modifying histones, coincident with the activation of -catenin/CBP target 
genes. Such relaxed chromatin state has been suggested to allow expression of genes not 
directly impacted by the -catenin/CBP complex (Valenta, Hausmann, & Basler, 2012a).  
Further, in addition to interacting with TCF/LEF, nuclear -catenin partners with many 
other transcriptional coactivators, including Yap/Taz, FoxM1, Bcl9, and Sox9, giving rise 
to different transcriptional outcomes (Valenta, Hausmann, & Basler, 2012b). We have 
previously demonstrated that two Hippo signaling effectors, YAP and its paralog TAZ, 
are associated with OSCC, with their transcriptional activities tracking with disease 
development and progression to aggressive state (Hiemer et al., 2015). GSEA of the 
YAP/TAZ-associated signature reveal a positive correlation between ICG-001 treatment 
and YAP/TAZ knockdown in HSC-3 cells, suggesting potential convergence of -catenin 
with YAP/TAZ in OSCC, as observed in other cancers (Rosenbluh et al., 2012).  
Although the preferred DNA-binding transcription factor partner for -catenin is 
TCF, -catenin can also interact with other transcription factors including HIF1, FOXO 
and NR5A2, driving expression of different subsets of target genes. Our analysis using 
TOPflash luciferase reporter assay confirms that ICG-001 inhibits -catenin/CBP activity 
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via TCF, although it is also possible that the -catenin/CBP complex interacts with other 
transcription factors known to bind -catenin. Thus, while standard gene reporter assays 
for -catenin activity, such as TOPflash, are not likely to reveal the spectrum of its 
functions, ICG-001 treatment signatures derived from differential gene expression 
analyses generate more realistic cell type-specific readouts of -catenin/CBP activities.   
To obtain a better insight into the effects of ICG-001 on -catenin transcriptional 
activity, we turned to computational methods to uncover gene expression signatures of 
ICG-001 and align them with -catenin pathway activities. We previously highlighted the 
power of integrating in vitro treatment signatures with large multi-omic data made 
available through consortia such as the TCGA network in order to further dissect their 
importance in primary human malignancies (Hiemer et al., 2015). Here, we applied this 
integrative approach to interrogate ICG-001 inhibition in OSCC in order to draw 
meaningful conclusions on the patho-clinical relevance of the in vitro treatment signature 
derived from OSCC cells. By projecting a core set of genes down-regulated in both HSC-
3 and CAL27 cells onto TCGA OSCC RNASeq data, we were first able to obtain 
estimates of ICG-001 inhibition scores across all samples, with the inhibition scores 
reflecting the overall expression levels of the entire gene set. Survival analysis revealed 
that patients in which the ICG-001 inhibited genes were overexpressed (i.e. patients with 
higher ICG-001 inhibition scores) showed a significantly worse prognosis, in turn 
suggesting that treatment of these patients with ICG-001 may indeed improve their 
overall survival. Additionally, ICG-001 inhibition scores were found to be significantly 
elevated in OSCC versus AE samples, with increasing scores associated with higher 
  
42 
tumor grade, highlighting that more aggressive OSCCs characterized by a less 
differentiated state, may indeed be more sensitive to ICG-001 treatment based on their 
transcriptional wiring.  
 
2.5 Conclusion 
While HNSCC has been recognized as a devastating disease that poses a major 
global health problem, current clinical management of this malignancy remains limited 
by factors such as treatment-associated morbidity, resistance to radiotherapy, and disease 
persistence/recurrence. Decoding the underlying molecular mechanisms involved in 
HNSCC development and progression to aggressive disease is critical to the discovery of 
new druggable targets and novel effective treatment options. Using cellular and animal 
models as well as human data, we demonstrated the contribution of the -catenin/CBP 
signaling axis to HNSCC, providing evidence that targeting this signaling activity may be 
a useful strategy to intercept this malignancy. 
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Figure 2.1 ICG-001 inhibits growth of OSCC cell lines and promotes an epithelial phenotype 
A. Immunofluorescence imaging of β-catenin localization in OSCC cell lines in response to ICG-001 treatment 
showing more focused membrane localization of -catenin, increased intercellular adhesion with a more pronounced 
epithelial phenotype. Size bars, 10 m. B. ICG-001 treatment promotes cell compaction as measured by the average 
cell size (n=15) captured in 1A. C. Increased junctional organization of β-catenin in immunofluorescence images 
shown in 1A was determined based on the thickness of β-catenin at the membrane (n=10). D. Determination of half 
maximal effective concentration (EC50) for ICG-001 effects in OSCC cell lines. Shown are graded dose response 
curves for ICG-001 in CAL27, HSC-3, SCC9 and SCC25 cell lines for 72 hours of treatment. Immunofluorescence 
images were quantified using ImageJ and compared using PRISM GraphPad. ** P < 0.001; *** P < 0.0001 unpaired t-
test.  
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Figure 2.2 Genome-wide transcriptional profiling of non-metastatic and metastatic OSCC cells treated with 
ICG-001 
A. Heatmap of microarray gene expression treatment signatures derived from metastatic HSC-3 and non-metastatic 
CAL27 cells. RNA was extracted and profiled using microarrays from each cell line and gene expression profiles were 
compared by differential expression testing (ICG-001 treatment versus DMSO vehicle; n=3 per treatment group, per 
cell line). Signatures were derived for each cell line by retaining genes with filtered-FDR q < 0.01 and absolute linear 
fold-change ≥1.5. Row z-scores of log-2 expression values per gene are shown. B. Metastatic HSC-3 cells display 
higher sensitivity to transcriptional dysregulation by ICG-001 treatment than less aggressive CAL27 cells. Venn 
diagram summarizing the size and overlap of treatment signatures in HSC-3 and CAL27 cells is shown. C. ICG-001 
impacts the expression of genes with roles in Wnt/-catenin signaling (blue), cell proliferation and survival (red), 
intercellular adhesion (green), and stem cell-like behavior (purple). Waterfall plot displaying log-2 fold-changes of 
gene expression for all genes included in either HSC-3 or CAL27 treatment signatures (n=2,847 genes) is shown. 
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Figure 2.3 Differential expression profiles and validation of key genes affected by ICG-001 in OSCC cells 
A. Heatmap of microarray gene expression levels pertaining to genes highlighted in Figure 2C, along with their log 
fold-change of expression upon ICG-001 treatment in HSC-3 and CAL27 cells. B. qRT-PCR validation (n=3) of 
microarray profiles for select target genes confirming changes in gene expression upon treatment with ICG-001. * P < 
0.05; ** P < 0.01; *** P < 0.001 unpaired t-test. 
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Figure 2.4 Gene set enrichment analyses reveal ICG-001 treatment targets β-catenin- and YAP/TAZ-mediated 
transcriptional activity in OSCC 
siRNA-mediated knockdown (KD) of CTNNB1, and YAP+TAZ was performed in HSC-3 cells, followed by gene 
expression profiling using microarrays. A ranked reference list of genes was generated in decreasing order of t-statistic 
for differential expression, obtained by comparing the KD (n=3) versus scrambled siRNA control (n=3) groups 
(n=23,744 and 23,466 genes for β-catenin and YAP/TAZ KD experiments, respectively). The ICG-001 treatment 
signature (both up- and down-regulated genes) were queried for enrichment with respect to each of the KD ranked 
reference gene lists. Mountain plots for GSEA with respect to β-catenin (A.) and YAP/TAZ (B.) KD indicate ICG-001-
up- and down-regulated genes are significantly skewed towards up- and down-regulation upon β-catenin or YAP/TAZ 
KD, respectively. Reported FDR q-values were computed as part of the GSEA software. 
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Figure 2.5 Connectivity map analyses of the ICG-001 treatment signature  
Top 20 mimicking (A) or antagonizing (B) molecular perturbations associated with the ICG-001 treatment signature in 
HSC-3 cells based on L1000 data from the Connectivity Map (cMAP) database. Heatmaps represent connectivity 
scores per treatment condition across the nine cell lines considered for score computation, with features ranked in 
decreasing order of the median connectivity score displayed in the “summary” field. Signatures positively correlated 
with ICG-001 inhibition include inhibition of MAPK and EGFR. Signatures negatively correlated with ICG-001 
inhibition include overexpression of cell cycle regulator cyclin D1 and inhibition of NFkB. CP: Chemical Compound; 
CTRL: Control; KD: Gene knock-down; OE: Gene over-expression; PCL: Perturbation class member. 
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Figure 2.6 ICG-001 inhibits OSCC growth and metastasis in vivo  
A. HSC-3 cells (0.5 × 106 cells/40 l DMEM) were lentivirally transduced with DsRed and injected into tongues of 
two-month old nude mice. Tumor formation and metastasis were visualized using IVIS fluorescent imaging at day 17; 
representative images for mice treated with ICG-001 (n=8; bottom) or DMSO vehicle (n=8; top), and for control mice 
(n=2) are shown. Total radiant efficiency of cells in the primary tongue tumor and of cells that metastasized to other 
organs was significantly reduced upon ICG-001 treatment for both the primary tongue tumor and whole body 
metastases (shown as the mean + S.D.). B. Caliper measurements confirmed significantly reduced primary tumor 
volume in ICG-001- compared to DMSO-treated mice starting at day 13 with continued trend until sacrifice at day 20. 
C. Harvested tumors were analyzed by H&E staining for differences in morphologies. ICG-001-treated tumors 
exhibited a capsular phenotype, in contrast to untreated tumors that showed streaks of invasive cells growing into the 
tongue stroma. Fraction of the total tissue taken up by invasive epithelial cells was quantified for vehicle- and ICG-
001-treated tumors (n=3 per treatment group).  D. Total tissue lysates were prepared from mouse tumors (n=4 per 
treatment group) and analyzed by immunoblot for E-cadherin and -catenin protein levels after normalization to 
GAPDH. Immunoblot and bar graphs displaying relative protein levels are shown. E. Treatment with ICG-001 alters 
localization of key epithelial and mesenchymal markers. Immunofluorescence imaging of E-cadherin, β-catenin and 
vimentin in tumors treated with either DMSO vehicle (top) or ICG-001 (bottom). ICG-001 enhanced the recruitment of 
E-cadherin and β-catenin to cell-cell contacts, while reducing the expression of vimentin. * P < 0.05; ** P < 0.005; 
unpaired t-test. 
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Figure 2.7 ICG-001 inhibition transcriptional signature is associated with clinical outcomes in primary human 
OSCCs 
A. Stratification of human OSCC samples using the ICG-001 inhibition gene expression signature from HNSCC cells. 
The TCGA OSCC RNASeq dataset (n=352) was projected onto a core set of genes down-regulated by ICG-001 in both 
HSC-3 and CAL27 cells (n=104 genes) using ASSIGN. The heatmap of the signature expression profile (displayed as 
row z-scores of log-2 expression values per gene) is shown, with the estimated ICG-001 inhibition ASSIGN scores 
highlighted above (purple). B. Overall patient survival curves with respect to ICG-001 inhibition score. OSCC patients 
with survival information (n=318) were first divided into two groups: ICG-001 high and low, n = 159 each based on the 
median ICG-001 inhibition scores and compared for their overall survival outcomes. Samples with higher ICG-001 
inhibition scores had a lower overall survival, with median survival estimates of 2.7 and 5.48 years in the high and low 
groups, respectively. Statistical significance of survival difference between groups was determined using a log-rank test 
C. ICG-001 inhibition scores with respect to OSCC tumor status. OSCC samples (n=320) have significantly higher 
  
50 
ICG-001 inhibition scores than adjacent normal epithelia (AE) (n=32). Statistical significance was determined using an 
unpaired t-test comparing the two groups. D. OSCC samples with known tumor grade status (n=311) were used to 
analyze the association of ICG-001 inhibition scores and tumor progression. A significant positive association was 
observed between ICG-001 inhibition scores and increasing tumor grade. Statistical significance of the association of 
the ICG-001 inhibition scores with respect to tumor grade was determined as described in the Methods section.  
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CHAPTER THREE: IDENTIFICATION OF NOVEL MARKERS OF STROMAL 
ACTIVATION IN OSCC 
3.1 Background 
It is well recognized that the tumor microenvironment, consisting of carcinoma 
associated fibroblasts (CAFs), endothelial cells and immune cells, is vital for carcinoma 
cell proliferation, invasion and metastasis. CAFs, due to their ability to produce and 
dynamically modulate extracellular matrix (ECM), play a particularly important role in 
tumor invasion and subsequent metastatic colonization of multiple cancers, including 
those of the head and neck (Calon, Tauriello, & Batlle, 2014; Curry et al., 2014; De 
Wever, Van Bockstal, Mareel, Hendrix, & Bracke, 2014; Routray, Sunkavali, & Bari, 
2013). CAFs also produce angiogenic factors, proteases, growth factors, immune 
response-modulating proteins, anti-apoptotic proteins, and signaling molecules - all 
highly relevant to tumor biology (Illustration 1.2). The cross-talk between tumor cells and 
CAFs is bi-directional, with fibroblasts evolving in parallel with tumor cells and 
undergoing phenotypic modifications in response to changes occurring in tumors 
(Routray et al., 2013). The specific mechanisms underlying these complex interactions 
are only beginning to be elucidated, and are likely to be influenced by the type of tumor 
and the local tissue microenvironment. 
The activated tumor stroma shares some similarities with generic wound repair, as 
well as tissue fibrosis. It can be viewed as a biological response to a disrupted or 
damaged epithelial layer with stromal activation representing a repair process to restore 
tissue integrity and homeostasis (Flier, Underhill, & Dvorak, 1986). The origin of CAFs 
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can be diverse and involve both local and distant reservoirs. Locally, CAFs can arise 
from resident tissue fibroblasts, where TGFβ, as well as a stiffening matrix can promote 
their differentiation to alpha smooth muscle actin (αSMA)-positive myofibroblasts 
(Barron & Rowley, 2012; Calon et al., 2014). Alternative local sources may include 
mesenchymal or adipose-derived stem cells (MSC or ASC), as well as endothelial cells 
that can give rise to CAFs through endothelial to mesenchymal transition (EnMT). In 
some tumors, epithelial tumor cells may acquire a CAF-like phenotype through epithelial 
to mesenchymal transition (EMT) (Kalluri, 2016). 
The importance of CAFs in oral cancer is supported by several reports that show 
correlation between the presence of αSMA-positive fibroblast cells and poor prognosis 
(Marsh et al., 2011; Vered et al., 2010). In a large study of OSCC patients, the abundance 
of myofibroblasts was the best independent predictor of patient mortality (De Wever et 
al., 2014). However, the source of these phenotypically-active fibroblastic cells in OSCC 
lesions and the mechanisms underlying their activation remain poorly understood. The 
progress in this field is hindered by the lack of reliable fibroblast-specific markers owing 
to the heterogeneity and remarkable plasticity of fibroblast cells. Importantly, a 
comprehensive analysis demonstrating the ability to identify such markers using high-
throughput, genome-wide data from bulk tumor gene expression profiling of squamous 
cell carcinomas is yet to be performed, and is crucial to the rapid discovery of robust 
CAF markers in these cancers.  
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3.2 Methods 
3.2.1 TCGA RNA-sequencing data processing 
mRNA-sequencing (RNASeq) data was downloaded for TCGA Head and Neck 
Squamous Cell Carcinoma (HNSC) cancer cohort using Firehose v0.4.3 corresponding to 
the February 4th 2015 Firehose release. RNASeq version 2 data pertaining to Level 3 
RSEM-normalized gene expression values was used. OSCC data was derived from the 
HNSC dataset by only including patients that corresponded to OSCC anatomic neoplasm 
subtypes, namely alveolar ridge, base of tongue, buccal mucosa, floor of mouth, oral 
cavity and oral tongue (n = 352). Adjacent morphologically normal epithelial (AE) 
samples were defined using TCGA sample barcoding information and used as a control 
group. Only genes having non-zero expression in at least one sample were retained in 
each of the analyzed datasets. 
3.2.2 Genome-wide collagen Nearest Neighbor (NN) analysis 
Mean collagen expression of COL1A1, COL1A2 and COL3A1 across all samples 
in the OSCC dataset was computed and used as a reference for fibroblast-specific marker 
expression. These values were then correlated genome-wide (n = 20,243) using Pearson 
correlation with rigorous sample permutation-based p-value calculation to assess 
statistical significance for each gene (n = 1,000), and false discovery rate (FDR) used for 
multiple hypotheses testing correction. A ranked list of genes in decreasing order of 
Pearson coefficient was generated and used in subsequent analyses. 
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3.2.3 Pan-cancer collagen NN enrichment analysis 
TCGA RNASeq gene expression data pertaining to Adrenocortical carcinoma 
(ACC), Bladder urothelial carcinoma (BLCA), Colon adenocarcinoma (COAD), Kidney 
renal clear cell carcinoma (KIRC), Acute myeloid leukemia (LAML), Liver 
hepatocellular carcinoma (LIHC), Lung adenocarcinoma (LUAD), Lung squamous cell 
carcinoma (LUSC), Pancreatic adenocarcinoma (PAAD), and Prostate adenocarcinoma 
(PRAD) was obtained as described for the HNSC dataset (see TCGA RNA-sequencing 
data processing). The described NN analysis was applied to each dataset, similar to 
OSCC (see Genome-wide collagen Nearest Neighbor (NN) analysis), yielding a ranked 
list of genes for each dataset sorted in decreasing order of Pearson correlation coefficient. 
The top 50 genes for each cancer type were then tested for enrichment against each of the 
other cancer types by a Kolmogorov-Smirnoff (KS) test (using the ranked list in the given 
cancer type as a reference). This yielded pairwise KS D statistics for all 11 cancer types. 
Since enrichment for a given pair of cancer types was tested in both directions, the two 
values were averaged. Cancer types were then clustered using hierarchical clustering with 
average linkage for the agglomeration rule. 
3.2.4 Stromal score and Tumor purity analyses 
Stroma signature scores based on the ESTIMATE algorithm(Yoshihara et al., 
2013), pertaining to RNASeqv2 data for HNSC samples were downloaded 
from http://ibl.mdanderson.org/estimate/. For OSCC tumor samples that had both stroma 
scores and gene expression values (n = 185), the association between tumor sample 
stroma score and mean collagen expression was assessed by Pearson correlation. 
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Estimates of tumor purity computed using the ABSOLUTE algorithm(Carter et al., 2012) 
were obtained for HNSC samples from the Broad Institute of MIT and Harvard. For the 
OSCC tumor samples that had both ABSOLUTE tumor purity estimates and gene 
expression values (n = 278), we applied a Pearson correlation to test for the association 
between tumor sample purity and the described mean collagen expression. 
3.2.5 Cell lines 
Tested and authenticated CAL27 cells were purchased from ATCC. HSC-3 cells 
were a kind gift from Roberto Weigert (NIH, Bethesda, MD), and were described 
previously(Patel et al., 2011). CAL27 and HSC-3 cells were cultured under standard 
conditions in DMEM (Mediatech, Herndon, VA) supplemented with 10% FBS (Sigma-
Aldrich). Fibroblast culture was established from human tongue OSCC specimens (see 
Human oral tissue specimens). Biopsy was cut into small pieces and dissociated 
enzymatically by 0.25% collagenase (Worthington Biochemical Corporation, Lakewood, 
NJ) in DMEM with 20% fetal bovine serum. Digested tissue was placed in a culture dish 
in 5 ml of DMEM with 20% fetal bovine serum and grown for 3–5 days. The resulting 
confluent culture was subsequently passaged in DMEM with 10% fetal bovine serum. 
3.2.6 Real-time quantitative PCR 
Total RNA was isolated using TRIzol reagent (MRC, Inc., Cincinnati, OH). Real-
time PCR was performed using the StepOnePlus™ Real-Time PCR System (Applied 
Biosystems, Carlsbad, CA). Briefly, 1 μg of total RNA was reverse transcribed with 
random hexamers in a total volume of 20 μl using a Transcriptor First Strand cDNA 
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Synthesis Kit (Roche, Tuscon, CA) according to the manufacturer’s protocol. The cDNA 
was diluted to 200 μl. The real-time PCR was carried out using SYBR® Green PCR 
Master Mix (Applied Biosystems) with 2 μl of diluted cDNA in triplicates with 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as the internal control. Real-time 
PCR was performed at 95°C for 10 min, followed by 40 cycles of 95°C for 15 sec and 
60°C for 1 min. Melting curve analysis of PCR products confirmed the absence of 
secondary products. The primer sequences used for real-time PCR are available upon 
request. 
3.2.7 Human oral tissue specimens 
This study has been designated exempt (IRB Protocol # H-32423) by the Boston 
University School of Medicine Institutional Review Board, as no human subjects were 
studied and experiments were performed using human oral tissue specimens. Tissue 
specimens were obtained from patients at Boston University Medical Center, and were 
acquired from scalpel-generated incisional biopsies of six tongue specimens representing 
benign hyperkeratosis and epithelial hyperplasia, 10 tongue ulcer specimens, as well as 
from surgical resections of moderately differentiated (n = 8) and poorly differentiated (n 
= 4) OSCCs of the lateral tongue border and of the floor of the mouth. For each 
condition, cytologically-normal adjacent epithelia were also obtained and analyzed. 
Benign epithelial hyperplasia, dysplasia, and OSCC regions, as well as adjacent epithelia, 
were defined by an onsite histopathologic examination and tissues were snap frozen at 
−80°C. A portion of the tissues were sectioned and used for hematoxylin and eosin 
(H&E) staining and immunofluorescence imaging. Sections (3 μm) of tissues were placed 
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on OptiPlus Positive-Charged Barrier Slides (BioGenex), deparaffinized, treated with 
Retrievit-6 Target Retrieval Solution (BioGenex), and then processed. OSCC tissues 
were lysed for biochemical analysis 
3.2.8 Immunohistochemistry and Immunofluorescence staining 
Immunohistochemistry was performed on formalin-fixed, paraffin-embedded 8 
μm oral mucosa tissue sections using the Vectastain ABC kit (Vector Laboratories, 
Burlingame, CA) and Vector ImmPress Rabbit or Rat-AP kit according to the 
manufacturer's instructions. Briefly, sections (5 μm thick) were mounted on APES 
(aminopropyltriethoxy silane solution)-coated slides, deparaffinized with Histo-Clear 
(National Diagnostics, Atlanta, GA), and rehydrated through a graded series of ethanol. 
Endogenous peroxidase was blocked by incubation in 3% hydrogen peroxide for 30 
minutes, followed by incubation with 0.15 M glycine for 45 minutes, and blocking buffer 
(3% BSA) for 1 hour. Sections were incubated overnight at 4°C with antibodies against 
PDGFRβ (rabbit polyclonal anti-PDGFRβ, Cell Signaling, Danvers, MA), Periostin 
(rabbit polyclonal anti-Periostin, Abcam, Cambridge, MA) Podoplanin (rat anti-human 
Podoplanin, eBioscience, San Diego, CA) and Smooth Muscle Actin (biotinylated mouse 
monoclonal anti-SMA, NeoMarkers, Fremont, CA). For picrosirius red staining, slides 
were prepared similarly and were placed following rehydration in prewarmed Bouins’ 
solution for 1 hour at 60°C, followed by 0.1% Direct red (Sigma-Aldrich, St. Louis, MO) 
in saturated aqueous picric acid for 30 minutes. After brief washing in water, slides were 
placed in 0.1% Fast green (Fisher Scientific, Pittsburgh, PA) in water for 10 minutes, 
quenched in 1% acetic acid, and dehydrated through a graded ethanol series. For all 
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immunofluorescence staining tumor samples were directly embedded in O.C.T. 
compound, flash frozen, and stored at -80°C. Staining was performed on 5 μm 
cryosections of tumor. Briefly, slides were blocked with a blocking solution (3% BSA 
[Sigma-Aldrich], and 0.1% Triton® X-100 in PBS) for 2 h. After washing, tissue sections 
were incubated at 4°C overnight with primary antibodies: rabbit polyclonal PDGFRB 
(Cell Signaling, Danvers, MA), mouse anti-E-Cadherin (BD Biosciences) and goat 
polyclonal VE-Cadherin (Santa Cruz, CA). After washing, tissue sections were incubated 
with secondary Ab: Alexa fluor 488 donkey anti-rabbit (Invitrogen, Grand Island, NY), 
Alexa fluor 594 donkey anti-mouse, and Alexa fluor 594 donkey anti-goat (Invitrogen, 
Grand Island, NY) for 1.5 h. Coverslips were mounted on slides using Vectashield with 
DAPI (Vector Laboratories, Burlingame, CA) and examined using a FluoView FV10i 
confocal microscope system (Olympus, Center Valley, PA) at 488 nm (green), 594 nm 
(red) and 405 nm (blue). 
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3.3 Results 
3.3.1 Collagen genes COL1A1, COL1A2 and COL3A1 are highly expressed in fibroblasts 
relative to OSCC cells 
Collagen type I, which is typically produced by fibroblasts, is the most abundant 
protein in human body and the main component of various connective tissues, including 
tumor stroma (Kalluri & Zeisberg, 2006; Karagiannis et al., 2012; Sweeney et al., 2008). 
CAFs are the principal producers of collagen and other ECM proteins in tumor stroma 
(Kalluri & Zeisberg, 2006; Karagiannis et al., 2012). Because type I collagen fibrils are 
usually associated with collagen type III we selected COL1A1, COL1A2, and COL3A1 
genes as representative markers of CAFs. We first validated expression 
of COL1A1, COL1A2, and COL3A1, in OSCC fibroblast pairs isolated from tumor or its 
adjacent stroma, as well as in two OSCC tumor cell lines, CAL27 and HSC-3, using 
quantitative PCR. We verified that the collagen genes were expressed at high levels 
specifically in the fibroblasts (Table 3.1). Of note, the mean collagen expression in the 
TCGA OSCC cohort was higher in tumor samples compared to adjacent, 
morphologically normal epithelia (AE), with a sustained elevated expression in tumor 
grade 1 to grade 3/grade 4 groups, suggesting an early activation of fibroblasts in primary 
OSCCs (ANOVA P < 0.0001; Fig. 3.1A). 
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3.3.2 Mean collagen expression correlates strongly with independent scores of stromal 
activity in OSCC 
To independently assess the reliability of collagen expression as a proxy for 
stromal infiltration, we correlated stromal score values generated using the ESTIMATE 
algorithm (Yoshihara et al., 2013) with the corresponding mean collagen expression (n = 
185). Remarkably, we found that the mean expression of the three chosen collagen genes 
was highly positively correlated (Pearson r = 0.88, P < 0.0001; Fig. 3.1B) with the 
ESTIMATE-based stromal scores derived using a gene signature comprising a total of 
141 genes (Yoshihara et al., 2013). Despite strict selection for inclusion, TCGA tissue 
samples may retain a heterogeneous mix of cell types, causing varying levels of tumor 
purity. To assess whether the expression of the three specific collagens simply reflected 
the level of overall tumor purity, we correlated the average collagen expression and 
OSCC tumor purity estimated using the ABSOLUTE algorithm (Carter et al., 2012). To 
this end, TCGA samples with matching RNASeq expression and ABSOLUTE-based 
tumor purity estimates (n = 278) were analyzed. We observed a moderate negative 
correlation between the two features (Pearson r = -0.32; P < 0.0001; Fig. 3.2), indicating 
that higher average fibroblast-specific collagen expression only partially explains 
corresponding lower tumor purity. Degree of immune cell infiltration would be a logical 
additional contributor to reduced tumor purity not captured by collagen expression. 
Taken together, these results suggest that, in the context of OSCC, the mean expression 
of these three collagens may serve as a good proxy for stromal infiltration. 
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3.3.3 Nearest neighbor analysis identifies potential stromal markers in OSCC 
We performed a genome-wide 'nearest neighbor' (NN) analysis using the TCGA 
OSCC dataset to identify genes whose expression best-correlated with the average 
expression of the three chosen collagen genes (see Methods). Among the top-ranking 
genes, we found primarily ECM-specific genes, such as collagen type VI 
(COL6A1, COL6A3), FBN1, ADAM12, SPARC, and POSTN (Fig. 3.3 and Table 
3.2). PDGFRB, which codes for receptor protein platelet-derived growth factor beta 
(PDGFRβ) was also found to be highly positively correlated (Pearson r = 0.85, FDR = 
0.0085), and was the highest-ranked transmembrane protein-encoding gene (ranked 25th 
out of 20,243 genes tested), suggesting that PDGFRβ could serve as a cellular marker of 
OSCC CAFs. Gene-set enrichment analysis (GSEA) confirmed a positive enrichment of 
genes involved in ECM organization and signaling by PDGF (Table 3.3) with respect to 
the average collagen expression. Also, the top 50 genes were found to be more highly 
correlated with each other within the OSCC sample group than within the AE samples 
(Fig. 3.4), suggesting a more coordinated expression of these genes in OSCCs compared 
to controls. Expression of select genes within the top 50 hits was further examined 
experimentally using quantitative PCR in OSCC fibroblast pairs and in OSCC tumor cell 
lines (data not shown). Whereas all of the assessed genes showed high expression in 
fibroblasts, several genes, including SPARC, ADAM12, TIMP2, MMP2, 
and COL5A2 were also expressed in carcinoma cells, albeit at lower levels. The 
remaining genes were either undetected or expressed at negligible levels in tumor cells, 
confirming their CAF-specific expression. It is important to note that gene expression in 
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tumor cell lines may not accurately reflect in vivo conditions, and that this should be 
further experimentally validated in patient tumors. 
3.3.4 PDGFRβ is a reliable marker of CAFs in OSCC 
To assess the expression and tissue localization of PDGFRβ in OSCC, 
immunostaining was performed in OSCC tumor tongue specimens and paired 
morphologically normal AE tissue (n=12). For comparison, PDGFRβ expression was 
analyzed in tongue specimens representing benign hyperkeratosis and epithelial 
hyperplasia (n=6), as well as tongue ulcer specimens (n=10). PDGFRβ localized to the 
blood vessels in AE tissue, consistent with a pericyte/smooth muscle cell expression (Fig 
3.5A). Similar expression patterns were also observed in the hyperkeratosis/hyperplasia 
specimens (Fig. 3.5A). Conversely, numerous fibroblasts expressing high levels of 
PDGFRβ were found in stroma surrounding tumor islands in all OSCC specimens 
(12/12), while no PDGFRβ expression was detected on tumor cells (Fig. 3.5). Note also 
the very close proximity of PDGFRβ-positive cells to carcinoma cells. An increased 
presence of the PDGFRβ-positive cells was also observed in ulcer (10/10) in the 
granulation tissue, which forms during the healing process (Fig. 3.5A). PDGFRβ was 
primarily expressed on fibroblasts, as well as cells surrounding capillaries and small 
blood vessels, and, occasionally, on dendritic cells. These observations are consistent 
with the notion that there are many similarities between inflammatory wounds such as 
ulcers and activated tumor stroma(Flier et al., 1986).  
Since periostin (POSTN) was among the ECM genes that were closely associated 
with the collagens (genome-wide rank = 18, Pearson r = 0.88; Table 3.2) and PDGFRβ in 
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the TCGA analysis, we also examined its expression in OSCC specimens. Periostin was 
abundant in collagen-rich stromal regions identified using picrosirius red staining and its 
expression overlapped with that of PDGFRβ (Fig. 3.5B). 
Given the close proximity of PDGFRβ-positive cells to carcinoma cells, it was 
important to determine whether carcinoma cells in the invasive tumor fronts also express 
PDGFRβ. Tumor specimens were double stained for PDGFRβ and a representative 
marker of squamous carcinoma cells, E-cadherin. As shown in Figure 3.6A there was no 
co-localization between these two markers. Because PDGFRβ can be expressed in 
pericytes, as well as fibroblasts, we next examined co-localization of PDGFRβ with VE-
cadherin, a specific marker of endothelial cells. VE-cadherin-positive cells were 
primarily found in the stromal compartments in close proximity to PDGFRβ-positive 
cells, which may represent pericytes (Fig. 3.6B). There was, however, no co-localization 
between these two markers. As alpha smooth muscle actin (αSMA) (Marsh et al., 2011) 
and podoplanin(Inoue et al., 2014) were previously reported to be expressed in OSCC 
CAFs, these markers were considered in our analysis. Of note, neither marker showed as 
high a correlation with the average collagen gene expression compared to PDGFR in the 
TCGA analysis (Pearson r = 0.51 and 0.21 respectively). Expression of αSMA in 
unaffected tongue tissues, hyperplasia and ulcer specimens was localized to 
pericytes/SMA cells around the blood vessels (Fig. S.2). Furthermore, in contrast to the 
prevalent PDGFRβ expression, αSMA-positive CAFs were only found in a subset of 
OSCC specimens (3/11) (Fig. S.2). It has been reported that αSMA is usually associated 
with moderately and poorly differentiated OSCC, but is infrequent in well differentiated 
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tumors (Rodrigues et al., 2014) and our results are consistent with this finding. 
Podoplanin was expressed primarily in lymphatic endothelial cells (Fig. S.3). In OSCC, 
podoplanin was weakly expressed in a subset of CAFs (3/11) and overlapped with that of 
αSMA (Fig. S.3). Since PDGFRβ and αSMA are also expressed in pericytes, their 
increased expression during tumor progression may, in part, reflect tumor-induced 
angiogenesis. 
3.3.5 PDGFRβ is a potential CAF marker in multiple cancers 
We considered other potential CAF markers from our NN analysis within OSCC 
TCGA data, including PDGFRα, FSP1/S100A4, VIM, and FAP; however, none of these 
markers showed as close an association with the average collagen expression as PDGFRβ 
(Table 3.2). To assess how closely-related different cancer types are with respect to their 
collagen-associated expression signatures, and to see whether some of the top hits 
including PDGFRB had implications beyond OSCC, we extended the described NN 
analysis to 10 additional TCGA cancer datasets (see Methods). These included nine 
carcinoma datasets, as well as a leukemia dataset (LAML) as a negative control of ECM 
behavior owing to its non-solid tissue origin. Clustering based on the similarity of their 
NN rankings with respect to average collagen expression as measured by a pairwise KS 
enrichment statistic yielded a clear segregation of cancer types, with most manifesting a 
high similarity in their list of collagen-correlated markers, and with LAML the only clear 
outlier, likely reflecting its non-solid origin (Fig. 3.7). Of note, the overlap between the 
top 50 genes of the five most closely related cancer types (OSCC, LUAD, LUSC, BLCA 
and PAAD; Fig. 3.7A), yielded a set of 11 genes that included PDGFRB (Fig. 3.7B). 
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Furthermore, PDGFRB was consistently found to be within the top 50 hits of each NN 
ranked list for a total of eight out of the 11 cancer types (with the exceptions being KIRC, 
LAML and LIHC), with a mean genome-wide rank of 28.5. Its correlation with mean 
collagen expression was statistically significant (FDR q ≤ 0.05) in all tumor types but 
LAML (FDR q = 0.089). 
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3.4 Discussion 
It is becoming increasingly accepted that CAFs and their products may promote 
several hallmarks of cancer, including those contributing to tumor invasion and 
metastasis (Kalluri & Zeisberg, 2006; Tommelein et al., 2015). The presence of CAFs 
could thus serve as a potential prognostic marker in multiple cancers, including OSCC. 
Identification of CAFs remains challenging due to the heterogeneity of CAF markers 
across different cancer types. This novel approach, combining a high-throughput gene 
expression analysis of large primary tissue datasets with experimental validation of 
OSCC specimens, permits relatively rapid and comprehensive characterization of CAF 
markers without having to resort to large-scale immunostaining experiments. Taken 
together, these results suggest that PDGFRβ is the most consistent cellular marker of 
stromal activation both during early and late stages of OSCC progression, and could be 
utilized for the isolation and further characterization of stromal fibroblasts in OSCC. 
Theses analyses also suggest that PDGFRβ may be similarly relevant in additional 
carcinomas, however, this should be further investigated. 
A large study of several tumors, which did not include OSCC, systematically evaluated 
expression of PDGFRβ as well as PDGFRα on fibroblasts and pericytes by 
immunohistochemistry (Paulsson et al., 2009). The data revealed a variable expression of 
these receptors in different tumors, with fibroblast expression of PDGFRβ most common 
in lung and colon tumors. Interestingly, stromal expression of PDGFRβ in breast cancer 
correlated with poor prognosis (Paulsson et al., 2009). It is important to note that in our 
study PDGFRβ was not expressed on carcinoma cells, however with the limited number 
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of specimens analyzed, we cannot exclude a possibility that PDGFRβ may be expressed 
in a subset of OSCCs, as has been shown for other cancers (Heldin, 2013; Jechlinger et 
al., 2006). Relevant to our findings, previous studies demonstrated elevated expression of 
PDGF primarily in tumor cells in OSCC (Li et al., 2005; Sasahira et al., 2014), 
suggesting a paracrine mechanism of fibroblast recruitment through a PDGF-PDGFRβ 
axis. Interestingly, many of the top-ranking ECM-specific genes in our analysis have 
previously been evaluated in OSCC and linked to tumor progression. Of particular 
interest are matricellular proteins, SPARC and POSTN. Elevated expression of both 
genes was documented in OSCC (Choi et al., 2008) and correlated with the presence of 
metastases (Aquino et al., 2013; Siriwardena et al., 2006). Furthermore, basal lamina 
components, NID2 and LAMA4 were previously investigated in OSCC (Franz et al., 
2010; Guerrero-Preston R, Soudry E, Acero J, Orera M, Moreno-Lopez L, Macia-Colon 
G, Jaffe A, Berdasco M, Ili-Gangas C, Brebi-Mieville P, Fu Y, Engstrom C, Irizarri R, 
Esteller M, Westra W, Kock W, Califano J, 2012). Franz et al. reported that stromal 
expression of laminin α4 chain, which is undetectable in healthy and hyperplastic 
mucosa, gradually increased in tumor grades 1 to 3 (Franz et al., 2010). On the other 
hand, increased hypermethylation of NID2 promoter was observed in OSCC samples, 
indicative of decreased gene expression (Guerrero-Preston R, Soudry E, Acero J, Orera 
M, Moreno-Lopez L, Macia-Colon G, Jaffe A, Berdasco M, Ili-Gangas C, Brebi-Mieville 
P, Fu Y, Engstrom C, Irizarri R, Esteller M, Westra W, Kock W, Califano J, 2012). 
However, expression of NID2 in the TCGA OSCC dataset was higher in tumor samples 
compared to adjacent normal epithelia with a sustained elevated expression in tumor 
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grades 1 to 3 (data not shown). It would be important to experimentally evaluate 
expression of NID2 mRNA and protein in OSCC specimens to clarify this inconsistency. 
Matrix metalloproteinases are multifunctional proteins that are central to tumor 
progression and metastasis (Brown & Murray, 2015). MMP2 was the highest-ranking 
MMP gene whose expression was found to significantly correlate with the collagen genes 
in our NN analysis. Elevated expression of MMP2 was previously reported in OSCC and 
was associated with more invasive phenotype (Jafarian et al., 2015). Another proteolytic 
family of enzymes related to MMPs is a disintegrin and metalloproteinase (ADAM) 
multifunctional gene family, which also regulates cancer cell proliferation and 
progression (Mochizuki & Okada, 2007). In particular, ADAM12 is overexpressed in 
various pathological conditions, including adenocarcinoma and breast and bladder 
cancer, as well as several fibrotic diseases (Nyren-Erickson, Jones, Srivastava, & Mallik, 
2013). In OSCC, increased expression of ADAM12 mRNA and protein has been 
observed and correlated with primary tumor size and tumor stage(Uehara et al., 2012). 
Two other related family members ADAMTS12 and ADAMTS2 were also among the 
top ranking genes in our NN analysis. Interestingly, ADAMTS12 has been shown to have 
both pro- and anti-tumorigenic activities, while very little is still known about the role of 
ADAMTS2 in cancer (Kelwick, Desanlis, Wheeler, & Edwards, 2015). To date, there are 
no reports on the expression of ADAMTS family members in OSCC. In addition to the 
genes discussed, there were additional stromal genes identified by the NN analysis, 
including CDH11, OLML3, FSTL1, AEBP1, VCAN, previously reported to correlate with 
tumor progression and metastasis in various cancers (Cheon et al., 2014; Gasi Tandefelt, 
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Boormans, Van Der Korput, Jenster, & Trapman, 2013; Torres et al., 2013). Elevated 
expression of CDH11 mRNA has indeed been observed in OSCC (Choi et al., 2008).  
The altered expression of stromal markers is consistently associated with poor prognosis. 
However, despite the increased interest in this field, the specific functional role of the 
stromal alterations in facilitating tumor progression is still poorly understood. A major 
limitation in studying CAF populations in vivo has been the lack of robust fibroblast 
markers that are both fibroblast-specific, and expressed in all fibroblast populations 
(Kalluri & Zeisberg, 2006). This body of work represents a new, unbiased approach to 
select CAF markers with relevance to OSCC for further validation and mechanistic 
studies, with the ultimate goal of identifying novel therapeutic targets for OSCC.    
3.5 Conclusion  
Here, I present an informatics-driven approach aimed at the rapid evaluation of 
fibroblast-specific markers in OSCC. Specifically, I highlight the relevance of PDGFRβ 
as a potential CAF marker in human OSCCs through a combination of high-throughput 
gene expression analyses of large primary tissue datasets, and experimental validation 
using a panel of OSCC specimens and cell lines. To allow for an unbiased identification 
of fibroblast-specific markers in OSCC, I first demonstrate how the average expression 
profile of genes encoding the three major interstitial collagens (COL1A1, COL1A2, and 
COL3A1), is indeed highly correlated with independent measures of stromal activity, and 
can be used as a reference to extract markers of activated fibroblasts in human OSCC. 
Next, I implemented a co-expression-based nearest-neighbor analysis in search for genes 
whose expression closely associated with average collagen expression profile using bulk 
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OSCC RNASeq data derived from the cancer genome atlas (TCGA). In this manner, I 
identified several candidate CAF-specific markers involved in regulating cell growth and 
extra-cellular matrix remodeling, including receptor protein PDGFRβ, among the top 
hits. Subsequent analyses of OSCC specimens demonstrated that PDGFRβ was 
abundantly expressed in stromal fibroblasts, while it was absent in tumor cells, with 
greater specificity compared to other previously investigated fibroblast markers such as 
αSMA or podoplanin. Additionally, PDGFRβ expression was found to be positively 
correlated with higher OSCC stage, indicating its potential use as a diagnostic marker. By 
then extending the collagen-based interrogation to multiple cancer types using TCGA 
RNASeq profiling data, I demonstrated the potential importance of PDGFRβ as a marker 
in other cancers. Overall, this approach represents a fast and simple method enabling an 
unbiased, genome-wide assessment for fibroblast-specific target selection. These results 
suggest that PDGFRβ is a reliable marker for identification of CAFs in OSCC, and a 
potential target for combinatorial therapy involving targeting of both the malignant cells 
and CAFs to abrogate microenvironment-directed tumor progression. Lastly, it provides a 
list of additional candidates that may serve as an important resource for CAF detection 
and characterization as part of the clinical and diagnostic management of OSCC and 
other carcinomas. 
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Table 3.1 qRT-PCR confirms fibroblast-specific expression of collagen genes  
Real-time quantitative PCR expression for genes COL1A1, COL1A2, and COL3A1 from pooled fibroblast cells isolated 
from OSCC (FibOSCC) and adjacent normal epithelium (FibAE) and OSCC epithelial cell lines (HSC-3 and CAL27) was 
determined. Fibroblast to cancer expression (represented as relative quantification or RQ) for each gene was calculated 
by averaging FibOSCC and FibAE, and CAL27 and HSC-3 values, respectively, normalizing the former value to 1. 
GAPDH was used as an internal control.  
 
Gene Cell type RQmean Average fibroblast to 
cancer expression 
COL1A1 FibOSCC, FibAE 1.03 1.0 
HSC-3, CAL27 0.000304 0.0003 
COL1A2 FibOSCC, FibAE 1.015 1.0 
HSC-3, CAL27 5.2787e-05 5.2e-05 
COL3A1 FibOSCC, FibAE 1.92 1.0 
HSC-3, CAL27 2.34e-07 1.2e-07 
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Table 3.2 Top hits from collagen-based Nearest Neighbor analysis in TCGA OSCC  
Top 30 genes ranked in decreasing order of their Pearson correlation co-expression with respect to the mean expression 
of COL1A1, COL1A2 and COL3A1. FDRs indicate permutation-based significance estimates after multiple testing 
correction genome-wide (n=20,243). The Gene identifier field represents both official HGNC gene symbols and Entrez 
gene IDs for each gene. 
Genome-
wide rank 
Gene Pearson r FDR 
1 COL1A2|1278 0.995374 0.0085 
2 COL1A1|1277 0.989481 0.0085 
3 COL3A1|1281 0.973356 0.0085 
4 ADAM12|8038 0.951104 0.0085 
5 COL5A1|1289 0.949272 0.0085 
6 COL6A1|1291 0.941982 0.0085 
7 COL5A2|1290 0.927702 0.0085 
8 COL6A3|1293 0.924237 0.0085 
9 OLFML2B|25903 0.923944 0.0085 
10 NID2|22795 0.907874 0.0085 
11 AEBP1|165 0.904228 0.0085 
12 TIMP2|7077 0.898573 0.0085 
13 DCHS1|8642 0.896597 0.0085 
14 MAGEL2|54551 0.895947 0.0085 
15 COL6A2|1292 0.894022 0.0085 
16 FBN1|2200 0.893822 0.0085 
17 LRRC15|131578 0.889592 0.0085 
18 SPARC|6678 0.88934 0.0085 
19 PCOLCE|5118 0.879776 0.0085 
20 MMP2|4313 0.875765 0.0085 
21 POSTN|10631 0.875661 0.0085 
22 KIAA1462|57608 0.873375 0.0085 
23 KIF26B|55083 0.871119 0.0085 
24 ADAMTS12|81792 0.864965 0.0085 
25 LAMA4|3910 0.859023 0.0085 
26 HMCN1|83872 0.855001 0.0085 
27 FAM198B|51313 0.851723 0.0085 
28 PDGFRB|5159 0.850889 0.0085 
29 VCAN|1462 0.850408 0.0085 
30 GLT8D2|83468 0.848443 0.0085 
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Table 3.3 Top enriched gene sets associated with increased collagen expression in TCGA OSCC  
Gene set enrichment analysis (GSEA) using canonical pathways from the molecular signature database (MSigDB) with 
respect to average collagen expression in TCGA OSCCs highlight enrichment for gene sets related to ECM 
organization, collagen formation and signaling by PDGF. Only gene sets with FWER < 0.05 are shown. NES: 
Normalized Enrichment Score. 
 
Gene set name Size NES FWER 
p-val 
NABA_CORE_MATRISOME 273 2.54 0 
NABA_ECM_GLYCOPROTEINS 194 2.47 0 
REACTOME_EXTRACELLULAR_MATRIX_ORGANIZATION 84 2.32 0.001 
NABA_ECM_REGULATORS 233 2.40 0.001 
KEGG_ECM_RECEPTOR_INTERACTION 83 2.30 0.002 
REACTOME_GLYCOSAMINOGLYCAN_METABOLISM 108 2.31 0.002 
REACTOME_NCAM_SIGNALING_FOR_NEURITE_OUT_GROWTH 64 2.31 0.002 
REACTOME_NCAM1_INTERACTIONS 39 2.25 0.008 
NABA_COLLAGENS 44 2.25 0.008 
KEGG_FOCAL_ADHESION 199 2.25 0.008 
REACTOME_AXON_GUIDANCE 241 2.22 0.011 
REACTOME_COLLAGEN_FORMATION 56 2.21 0.012 
REACTOME_CHONDROITIN_SULFATE_DERMATAN_SULFATE_METABOLISM 47 2.20 0.014 
REACTOME_SIGNALING_BY_PDGF 118 2.20 0.014 
NABA_PROTEOGLYCANS 35 2.19 0.019 
REACTOME_INTEGRIN_CELL_SURFACE_INTERACTIONS 79 2.15 0.033 
REACTOME_DEVELOPMENTAL_BIOLOGY 385 2.15 0.033 
KEGG_NEUROACTIVE_LIGAND_RECEPTOR_INTERACTION 269 2.14 0.035 
REACTOME_HEPARAN_SULFATE_HEPARIN_HS_GAG_METABOLISM 51 2.14 0.036 
NABA_BASEMENT_MEMBRANES 40 2.13 0.039 
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Figure 3.1 Collagen expression is elevated early in OSCC and can be used as a proxy to identify potential OSCC 
CAF markers  
A. Box plot of average fibroblast-specific collagen expression (COL1A1, COL1A2, COL3A1) with respect to tumor 
grade pertaining to OSCC TCGA data. B. Correlation of mean collagen expression with respect to scores of stromal 
activity derived using the ESTIMATE algorithm. AE: Adjacent normal epithelium. 
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Figure 3.2 Mean collagen expression is inversely correlated to tumor purity estimates in TCGA OSCC samples 
Scatter plot of mean collagen expression vs. tumor purity estimates derived using the ABSOLUTE algorithm 
highlighting a moderate negative correlation (Pearson r = -0.32, P < 0.0001).  
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Figure 3.3 Nearest neighbor (NN) gene expression analysis based on the mean collagen expression identifies 
potential stromal-specific markers in TCGA OSCC 
Shown is a heatmap of gene expression levels of the top 50 hits (53 including COL1A1, COL1A2 and COL3A1) 
resulting from the NN analysis. Top hits include genes encoding pro-migratory and matrix remodeling factors, 
including PDGFRB, which was the highest ranked receptor-encoding gene. Only samples with known tumor grade are 
shown. AE: Adjacent normal epithelium.  
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Figure 3.4 Expression of candidate CAF markers are more tightly co-expressed in OSCC relative to adjacent 
normal epithelium tissue  
Pairwise gene expression Pearson correlation of the top 50 hits from collagen NN analysis in (A.) tumor and (B.) 
control TCGA OSCC samples. 
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Figure 3.5 PDGFRlocalizes primarily to the surrounding stroma in OSCC  
A. PDGFR staining is absent in adjacent epithelium and hyperplasia samples, but is present in ulcer and OSCC 
specimens. Red arrows indicate blood vessels and green arrows indicate fibroblasts. B. Picrosirius red staining of 
collagen 1 and 3 fibers (left) and immunostaining of PDGFR (middle) and additional marker periostin (right) that 
were identified from the collagen NN analysis. 
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Figure 3.6 PDGFRdoes not co-localize with tumor cells and endothelium  
Double immunofluorescence staining of PDGFRE-Cadherin (A.), and PDGFR/VE-Cadherin (B.) on cryosections 
from oral tumor biopsies. Representative images are shown for four tumors. 
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Figure 3.7 Pan-cancer NN analysis reveals PDGFRas a potential CAF marker in multiple cancer types  
A. Heatmap of average pairwise Kolmogorov-Smirnoff (KS) D statistics using the top 50 genes in the collagen NN 
cancer analysis of each of 11 cancer types. B. Venn diagram of top 50 genes in collagen NN ranked list within the five 
most closely related cancers (based on the average KS D statistic in panel A). Core overlap comprises 11 genes, which 
includes PDGFR, highlighted in red. ACC: Adrenocortical carcinoma; BLCA: Bladder urothelial carcinoma; COAD: 
Colon adenocarcinoma; KIRC: Kidney renal clear cell carcinoma; LAML: Acute myeloid leukemia; LIHC: Liver 
hepatocellular carcinoma; LUAD: Lung adenocarcinoma; LUSC: Lung squamous cell carcinoma; PAAD: Pancreatic 
adenocarcinoma; PRAD: Prostate adenocarcinoma. 
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CHAPTER FOUR:  MULTI-OMIC INVESTIGATION OF CANDIDATE 
DRIVERS OF ONCOGENIC PATHWAY ACTIVITY 
4.1 Background 
Advances in high-throughput sequencing technology has led to a rapid rise in the 
availability of large multi-omic datasets through compendia such as the Cancer Cell Line 
Encyclopedia (CCLE), The Cancer Genome Atlas (TCGA), the Genotype-Tissue 
Expression (GTEx), and others (Ardlie et al., 2015; Jordi Barretina et al., 2012; Chang et 
al., 2013) (Fig. 1.1). These data include genetic alterations, comprising somatic copy 
number alterations (SCNAs) and somatic mutations, epigenetic information, such as 
microRNA expression and DNA methylation, as well as gene expression profiling 
through microarray or RNA-sequencing (RNASeq) technology, across tens of thousands 
of samples representing varying biological contexts (Table 1.1). Concomitantly, several 
computational methods have been developed and applied to effectively query and 
integrate different types of genome-wide datasets in order to make meaningful 
predictions about the underlying biological processes driving the phenotypes of interest 
(Drier, Sheffer, & Domany, 2013; Kristensen et al., 2014). An important application of 
such methods is the identification of recurrent genomic alterations, and their potential 
effects on downstream pathway activity or phenotypes. For example, in many cancers, 
samples exhibiting elevated activity of a given oncogenic signature may be enriched for, 
or driven by functionally-relevant somatic mutations or SCNAs. Identifying such 
associations may help unravel underlying mechanisms contributing to abnormal pathway 
activity, further enabling disease subtyping and sample classification (Bea et al., 2005; 
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Monti et al., 2012; Savage et al., 2003). Alternatively, linking these genomic features 
with phenotypic readouts such as drug sensitivity may support the discovery of novel 
druggable targets and further guide precision medicine regimens (Bild et al., 2006; 
Daemen et al., 2013; Heiser & Sadanandam, 2012).  
Recently, computational methods have been developed to identify subsets or 
combinations of genomic features that are collectively associated with a given phenotypic 
response (Ciriello, Cerami, Sander, & Schultz, 2012; J. W. Kim et al., 2016; Leiserson, 
Blokh, Sharan, & Raphael, 2013; Vandin, Upfal, & Raphael, 2012). These methods, 
while having the capacity to find alternative drivers contributing to the same downstream 
effect, tend to rely on restrictive properties such as mutual exclusivity of features, or 
feature recurrence in a subset of samples independent of the target phenotypic profile 
under consideration. More importantly, not all methods support the joint analyses of 
features including SCNAs and somatic mutations, with possible extension to other 
genomic data, while also allowing for multiple statistical feature scoring functions, along 
with a rigorous assessment of the statistical significance of the discovered associations. 
Finally, a user-friendly and flexible programming package supporting the rapid screening 
for candidate drivers given a set of ranked genomic features is currently lacking, and 
would prove extremely useful for incorporation in analytical pipeline frameworks aimed 
at the generation of novel biological hypotheses. In this chapter, I present a novel 
stepwise-heuristic search framework that attempts to address these issues, and 
demonstrate its performance and applicability through a series of vignettes that utilize 
simulated as well as real multi-omic datasets of cancer cell lines and human tumors.  
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4.2 Methods 
4.2.1 The CaDrA algorithm 
An overview of CaDrA’s workflow is summarized in Figure 4.1. CaDrA takes as input 
the sample ranking induced by a sample-specific measurement, a matrix of binary 
features (1/0 indicating the presence/absence of a given feature in a sample), and a 
scoring method specification to measure the significance of the association between the 
occurrence of alteration events and the defined sample ranking. The pre-defined sample 
ranking can be based on quantitative estimates of a gene expression, a signature or 
pathway activity, or other experimentally-derived measurements. Each row in the matrix 
of binary features denotes the presence or absence of a somatic alteration (mutation, 
CNA, or other) in each of the samples in the ranked cohort. The score function is a 
measure of the left-skewness of a binary vector with respect to the sample ranking. The 
more the occurrences of an alteration are skewed towards higher rankings (i.e., the more 
the 1’s in the feature vector are skewed towards the left), the higher the score. The scores 
currently implemented are the Kolmogorov-Smirnov (KS) test, and the Wilcoxon rank-
sum test, but additional scoring functions can easily be added. 
Given the sample ranking, the matrix of binary features, and the score of choice (KS or 
Wilcoxon), CaDrA implements a step-wise greedy search: it begins by first selecting the 
single feature that maximizes the score (Step 1; Figure 4.1). It then generates the union 
(logical OR) of this starting feature with every other remaining feature in the dataset and 
computes scores for the obtained ‘meta-features’ (Step 2; Figure 4.1); it selects a 2nd 
feature that, added to the first (as a union), maximally increases the score – which will 
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then serve as the new top reference hit (Step 3; Figure 4.1). Repeating this process until 
no further improvement to the cumulative score can be attained, the search output is a set 
of features (i.e. a meta-feature) whose union has the (local) maximum skewedness score 
with respect to the input sample ranking. The significance of a CaDrA search and its 
cumulative score are determined by generating an empirical null distribution of scores 
based on the exact same data and search parameters, but with randomly-permuted sample 
rankings, providing a permutation p-value per search result. 
 
4.2.2 CaDrA features 
Search modes: CaDrA supports multiple search modalities: it allows for the selection of a 
user-specified feature from which to start the search (rather than selecting the feature 
with highest score as depicted in Step 1 of Figure 4.1); alternatively, since the greedy 
search is not guaranteed to find the global maximum, it also allows for a “top-N” search 
modality, whereby the search is started from each of the first N features (as measured by 
their individual skewedness scores), and the result of the best search can be determined 
by selecting the set of features with the best cumulative score over the top-N runs. 
 
Visualization of search results: For a given search, CaDrA outputs a set of features 
(meta-feature), which can be visualized as a ‘meta-plot’. This includes (panels from top 
to bottom): an area plot of the sample-specific measurements used to obtain the sample 
ranks; a color-coded matrix of all features in the meta-feature (in the step-wise order that 
they were added), one feature per row, with the corresponding union of the meta-feature 
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(red) last; and a corresponding enrichment score (ES) plot below. Additionally, top-N 
search results can be visualized for overlapping features to evaluate robustness across 
different search starting points. 
 
Parallelization support: The generation of the empirical null distribution for significance 
testing is typically done for ≥ 500 iterations (i.e. permuted sample ranks). In order to 
speed up this potentially time-consuming task, CaDrA supports exploiting parallel 
computing with the help of the parallel R package functionality, should multiple compute 
cores be available. 
 
Permutation caching: Since the generation of the null distribution used for significance 
testing is a time-consuming step, and since the null distribution of scores depends solely 
on the feature dataset and the search parameters specified (scoring method, starting 
feature versus top-N search mode etc.), and not on the input sample ranking, we can 
implement cacheing of the null distribution corresponding to each dataset and search 
parameters. When submitting multiple subsequent queries (each with its own sample 
ranking) that utilize the same dataset and search criteria, CaDrA can then fetch the 
corresponding cached null distribution to generate permutation p-values almost 
instantaneously, avoiding the need for repetitive computation, thus significantly reducing 
overall query run time.  
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4.2.3 Data availability and processing 
CaDrA is freely available for download and use as a documented R package under the 
github repository https://github.com/montilab/CaDrA, and will further be deposited and 
maintained for future use under Bioconductor, including complete code, example use-
cases and results pertaining to this manuscript. RNASeq, DNA copy number (GISTIC2) 
and mutation data for the TCGA BRCA cohort were downloaded using Firehose v0.4.3, 
corresponding to the Feb 4th 2015 (RNASeq) and the Jan 28th 2016 Firehose release 
(SCNA and somatic mutations). Somatic mutation data was processed at the gene level 
by assigning either 1 or 0 based on the presence or absence of any given mutation in that 
gene, respectively (excluding synonymous mutations). RNASeq version 2 data 
corresponding to Level 3 RSEM-normalized gene expression values were used. CCLE 
genomic data were downloaded from https://portals.broadinstitute.org/ccle and processed 
as previously described(J. W. Kim et al., 2016). Somatic mutation binary calls per gene 
were used, and SCNA data was processed using GISTIC2 (Mermel et al., 2011) with all 
default parameters barring the confidence level, which was set to 99%. ActArea estimates 
pertaining to drug treatment sensitivity across CCLE samples was used as previously 
described (Jordi Barretina et al., 2012). In all cases presented, SCNA and somatic 
mutation data were jointly analyzed as a single input dataset to CaDrA, thereby including 
samples for which both data were available. All input data to CaDrA were further pre-
filtered so as to exclude alteration frequencies below 3% and above 60% to reduce 
feature sparsity and redundancy, respectively, across samples (CaDrA’s default feature 
pre-filtering settings).  
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4.2.4 Simulated data generation 
To evaluate both the sensitivity and specificity of CaDrA, we generated simulated data to 
represent cases where there was a mix of left-skewed (“true positive”) and randomly 
distributed (“null”) features, as well as cases where there were only null features. The 
left-skewedness of a feature is a measure of its association with the sample ranking, since 
samples are sorted from left (high rank) to right (low rank). The design and parameter 
specification of the simulated data matrix is shown in Illustration 4.1. Each feature/row is 
a binary (0/1) vector, with 1 (0) in the ith position denoting the occurrence (non-
occurrence) of the genetic event (e.g., SCNA or mutation) in the ith sample. This 
simulation of binary features relies on the following parameters: 
 
N: Dataset sample size (number of columns in the matrix) 
n: Total number of features in the dataset (number of rows in the matrix) 
p: Number of true positive features generated per dataset (a positive feature is a feature 
whose distribution of events (i.e. the number of 1’s) is significantly associated with the 
sample ranking, i.e., left-skewed). 
f:  Left-skew proportion. The proportion of samples that are cumulatively left-skewed in 
the sample ranking.  
λ: The mean (and variance) of the Poisson distribution from which the number of events 
in the null features is sampled. This is equal to the number of 1’s per skewed positive 
feature. A Poisson distribution is used so that we can partially control (through the mean) 
the number of 1’s in a null feature. 
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The resulting simulated binary data matrix will consist of two main types of features: 
True Positive (TP) features: A total of p TP features are generated. Events (i.e., 1’s) are 
assigned to the TP features in a mutually exclusive fashion, with each of these features 
having (f×N) / p entries set to 1, with their cumulative OR yielding an N-sized vector 
with the left-most f×N entries set to 1’s. For example, if we generate data for 100 samples 
and 5 positive features, with the left-skew proportion set to 0.5, each non-overlapping 
feature will have 10 among the 50 left-most entries (columns) set to 1, such that the union 
(logical OR) of the 5 features will have 1’s in the first 50 entries. 
 
Null features: Null features are generated for a total of (n - p) features. To generate these 
features, we sample the number of 1’s per null feature based on a Poisson distribution 
with mean parameter λ = (f×N) / p. In this fashion, the number of 1’s in the null features 
will have a distribution centered on the corresponding number for the TP features. For 
instance, if we generate data for 100 samples and 5 TP features with left-skew proportion 
f = 0.5, then each of the TP features will have ten 1’s, and each of the remaining 995 null 
features will have a number of 1’s sampled from Poisson (λ=10), uniformly distributed 
over the N samples.  
A schematic representation of the simulated data, along with the parameters that define 
its composition is shown in Figure 4.2. 
4.2.5 Evaluation of CaDrA performance on simulated data 
Evaluation of CaDrA performance was performed considering two main scenarios: a) 
True positive datasets: Data containing both true positive and null features (where the 
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sensitivity of CaDrA is tested); and b) Null datasets: Data containing only null features 
(where the specificity of CaDrA is tested), with the following parameter specifications 
for data generation: 
N = {50, 100, 250 and 500} 
n = 1000 
p = 5 
f = 0.5 
CaDrA was run using default input parameters, with each search run returning a meta-
feature which had the best score, along with a permutation p-value based on the empirical 
null search distribution (Fig. S.4). These results were then used to determine performance 
estimates for different sample sizes, composition (i.e. distribution of TP versus null 
features per returned meta-feature), size (i.e. the number of features within the returned 
meta-feature) and statistical significance of the returned meta-features.  
4.2.6 YAP/TAZ signature projection and assessment in TCGA BRCAs 
A signature comprising YAP/TAZ-activating genes (n=717) in MDA-MB-231 cells was 
obtained based on a previous study (Enzo et al., 2015). The gene set was projected in the 
space of TCGA BRCA RNASeq data (n=1,186 samples) and per-sample estimates of 
YAP/TAZ activity were derived using ASSIGN (Shen et al., 2015), which was then used 
as a continuous ranking variable with CaDrA. The association of YAP/TAZ activity with 
respect to the presence or absence of the identified meta-feature using CaDrA, and BRCA 
subtype (i.e. triple- negative status) was determined using a linear regression model. 
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4.2.6 Cell culture, siRNA knockdown and qRT-PCR 
HS578T BRCA cells were purchased from ATCC and cultured using media and 
conditions suggested by ATCC. For RNA interference, cells were transfected using 
RNAiMAX (thermofisher) with control siRNA (Qiagen, 1027310) or an equal molar 
mixture of siRNA targeting, RELN (Sigma), RBCK1 (Sigma), or TAZ and YAP. 48 
hours post transfection, RNA was extracted from cells using RNeasy kit (Qiagen) and the 
synthesis of cDNA was performed as previously described(Hiemer, Szymaniak, & 
Varelas, 2014). Quantitative real-time PCR (qRT-PCR) was performed using Taqman 
Universal master mix II (thermofisher) and measured on ViiA 7 real-time PCR system. 
Taqman probes used included those recognizing CTGF (thermofisher Hs00170014_m1), 
CYR61 (thermofisher Hs00155479_m1), RELN (thermofisher Hs01022646_m1), 
RBCK1 (thermofisher Hs00934608_m1), and GAPDH (thermofisher 4326317E). 
Expression levels of each gene were calculated using the ΔΔCt method and normalized to 
GAPDH. Knockdown efficiency of YAP, TAZ, RELN and RBCK1 was verified for each 
experiment. RBCK1 knockdown in HS578T cells was 85% (±18.2). Basal RELN levels 
in HS578T cells were low, and relative knockdown in these cells was 28.3% (±14.1). 
Data from qRT-PCR experiments are shown as mean ± S.D., with each knockdown 
compared with respect to the scrambled control using an unpaired two-tailed Student's t-
test. 
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4.2.7 CaDrA search parameters 
For evaluation using genomic data, CaDrA was run in the top-N mode using the default 
of N=7, choosing the best resulting meta-feature. (see Methods; CaDrA features: Search 
modes). For evaluation of simulated data, only the top-scoring feature was considered as 
a starting feature per search run (i.e. N=1). All other default input search parameters were 
used for all cases presented. 
 
4.3 Results 
4.3.1 CaDrA approach overview 
An overview of CaDrA’s workflow is summarized in Figure 4.1. CaDrA 
implements a step-wise heuristic approach that searches through a set of binary features 
(each represented as a 1/0-valued vector, indicating the presence/absence of a SCNA, 
somatic mutation, or other (epi)genetic alterations, across samples), and returns a final 
subset of features whose union (logical OR) defines an alteration ‘meta-feature’ that is 
maximally associated with the defined sample ranking provided as input (see Methods). 
The strength of the association of a meta-feature with a sample ranking is a function of 
the skewedness of the alterations’ occurrences with respect to that same sample ranking. 
The input sample ranking is usually a function of a sample-specific measurement, e.g., 
the activity level of a pathway, the response to a targeted treatment, the expression level 
of a given transcript or protein, etc. Therefore, the meta-feature returned by the search is 
the set of features maximally predictive of that same sample-specific measurement 
variable. CaDrA allows for multiple modes to query ranked binary datasets with user-
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specified parameters defining search criteria, enables rigorous permutation-based 
significance testing of results, and reduced computation time by exploiting pre-computed 
score distributions and parallel computing, when available (see Methods). 
4.3.2 Analysis of simulated data to evaluate CaDrA performance 
To assess the overall performance of CaDrA to recover (statistically) significantly 
associated meta-features, I simulated two types of datasets for a range of sample sizes: i) 
the true-positive datasets consist of both left-skewed (i.e. true positive with skewness 
concordant with sample ranking) as well as uniformly distributed (i.e. null) features 
(Illustration 4.1); and ii) the null datasets consist of null features only (see Methods). 
This enabled us to estimate the overall sensitivity and specificity of CaDrA using the true 
positive and null datasets, respectively. By running CaDrA on multiple simulated datasets 
(n=500 true positive and null datasets, each), I first assessed the resulting meta-features 
based on the number of true positive features and the total number of features contained 
within each returned meta-feature (the meta-feature size; Fig. 4.2A, C). The true positive 
datasets had a maximum of 5 positive features to be detected, while the maximum 
number of features CaDrA was allowed to add (i.e. the maximum meta-feature size) was 
set to 7 (default), to evaluate the ability of the search to recover all but no more than the 
positive features. The true positive rate (TPR) and false positive rate (FPR) of CaDrA on 
the simulated positive and null data, respectively, for different sample sizes and for = 
0.05 is shown in Figure 4.2B and 4.2D, and was calculated as the fraction of searches 
returning meta-features with permutation p-value significant at =0.05. This TPR was 
estimated for different number of recovered true positive features (in the true positive 
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datasets) and is summarized in Table 4.1. The FPR was estimated for different the 
number of returned features (by definition, false positives) in the null datasets, and is 
summarized in Table 4.2. CaDrA returned all of the simulated true positive features with 
100% TPR for sample sizes larger than N=100. CaDrA also yielded a very high mean 
TPR of >95% at N=100, with the sensitivity dropping to 7.69% only at the smallest 
sample size of N=50. Further, when applied to the null datasets (Fig. 4.2C), the majority 
of meta-features returned by CaDrA were correctly deemed as non-significant at =0.05, 
with a maximum mean FPR of 7.2% for the lowest sample size analyzed (N = 50; Fig. 
4.2D). These results suggest that CaDrA requires mid- to large-sized datasets for 
sufficient sensitivity, while maintaining high specificity at all sample sizes assessed. 
4.3.3 CaDrA identifies known regulators of Ras/Raf/Mek/ERK signaling sensitivity 
The mitogen-activated protein kinase (MAPK) kinase (MEKK) / extra-cellular 
signal-regulated kinase (ERK) pathway is a well-conserved kinase cascade known to play 
a regulatory role in cell proliferation, differentiation, and survival in response to 
extracellular signaling (Burotto, Chiou, Lee, & Kohn, 2014; Cargnello & Roux, 2011; E. 
K. Kim & Choi, 2010). Increased MAP/ERK kinase (MEK) activity is a feature of many 
cancers, and is often triggered by missense mutations in BRAF and NRAS, two upstream 
oncogenes and potent regulators of Ras/Raf/Mek/ERK signaling (Burotto et al., 2014; 
Cantwell-Dorris, O’Leary, & Sheils, 2011). Specifically, the BRAFV600E mutation 
accounts for >90% of BRAF mutations and has been identified as a driver of certain 
tumors, including melanoma and colorectal cancers, by activating MEK downstream, and 
is generally found to be mutually exclusive to NRAS mutations(Cantwell-Dorris et al., 
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2011; Sensi et al., 2006). Small molecules targeting these mutated proteins have been 
shown to be effective in treating these cancers via inactivation of Ras/Raf/Mek/ERK 
signaling (Jordi Barretina et al., 2012; Chapman et al., 2011; Johnson & Puzanov, 2015; 
Roberts & Der, 2007). To highlight CaDrA’s ability to recover independent genomic 
features that may confer hypersensitivity of cancer cells to targeted small molecule 
treatment, I utilized drug sensitivity profiles for MEK inhibitor AZD6244 (Yeh et al., 
2007), along with matched genomic data from CCLE. Specifically, I used per-sample 
estimates of ‘ActArea’ or area under the fitted dose response curve, a metric that has been 
shown to accurately capture drug response behavior (Jang, Neto, Guinney, Friend, & 
Margolin, 2014), to rank cell lines from high to low sensitivity, as well as data 
comprising somatic mutations and SCNAs as the binary feature matrix (see Methods). 
CaDrA was then run to look for a subset of features associated with increased sensitivity 
to treatment with AZD6244 (i.e. increased ActArea scores). The resulting feature set (i.e. 
meta-feature) is shown in Figure 4.3. Remarkably, CaDrA selected the BRAFV600E and 
NRAS somatic mutations in the first two iterations, respectively. Subsequent iterations 
identified mutations in APAF1, TGFBR2 and AMHR2, before terminating the search 
process. APAF1 is a pro-apoptotic factor and known regulator of cell survival and tumor 
development (Ferraro, Corvaro, & Cecconi, 2003), the depleted expression of which has 
been observed in malignant melanoma cell lines and specimens (Soengas, Gerald, 
Cordon-Cardo, Lazebnik, & Lowe, 2006). TGFBR2 and AMHR2 are both type II 
receptors functioning as part of the transforming growth factor (TGF)/bone 
morphogenetic protein (BMP) superfamily, together serving as mediators of cellular 
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differentiation, proliferation and survival, and play important roles in directing epithelial-
mesenchymal transition (EMT) (Rojas, Padidam, Cress, & Grady, 2009; Stone et al., 
2016). Notably, MAPK signaling activity can also be regulated by TGF/BMP stimulation 
(Chapnick, Warner, Bernet, Rao, & Liu, 2011; Derynck & Zhang, 2003; Moustakas & 
Heldin, 2005), suggesting that these mutations are potential independent drivers of 
increased MEK signaling, and hence, increased sensitivity to treatment with AZD6244. 
Next, I extended this analysis of cancer cell line sensitivity profiles to alternative small 
molecules targeting MEK (PD-0325901), as well as RAF (PLX4720 and RAF265). The 
meta-features associated with increased sensitivity to each of the four drug treatments 
assessed are shown in Figure 4.4 and summarized in Table 4.3. Importantly, both 
BRAFV600E and NRAS mutations were identified as candidate drivers of sensitivity to 
MEK inhibition by AZD6244 and PD-0325901. Furthermore, the BRAFV600E mutation 
was returned by CaDrA for the four independent queries, highlighting its association with 
increased sensitivity to inhibitors targeting the same protein (BRAF) as well as its 
downstream effector (MEK). Collectively, these results confirm CaDrA’s capability to 
accurately identify upstream drivers of cellular response to treatment that are both 
components of independently-linked pathways, as well as part of the same signaling 
branch, which in turn suggests their role in driving the disease state of interest. 
4.3.4 CaDrA reveals novel drivers of oncogenic YAP/TAZ activity in human breast 
cancer 
The Hippo signaling pathway is a well-characterized highly conserved and 
tightly-regulated developmental pathway known to play an essential role in cell 
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proliferation and survival(Varelas, 2014). YAP (Sudol, 1994) and TAZ (Kanai et al., 
2000) serve as central downstream transcriptional effectors of the pathway, with 
transcriptional activity restricted by Hippo pathway signals that lead to YAP/TAZ 
nuclear exclusion and degradation. Aberrant nuclear YAP/TAZ localization and activity 
is associated with a range of cancers, including breast carcinomas (Hiemer et al., 2015; 
Moroishi et al., 2015; Zanconato et al., 2015, 2016). To identify alternative genetic 
events that can potentially explain the elevated YAP/TAZ activity exhibited in some 
human breast cancers, I applied CaDrA using genomic data from the TCGA breast 
carcinoma (BRCA) sample cohort, along with corresponding per-sample estimates of 
YAP/TAZ activity derived using a gene expression signature of YAP/TAZ knockdown in 
MDA-MB-231 cells (see Methods). Samples with available RNASeq, somatic mutation 
and SCNA profiles (n=957) were first ranked in decreasing order of their overall 
YAP/TAZ activity estimates. The ranked binary mutation and SCNA features were then 
used as input to CaDrA. In the first iteration, CaDrA identified the top scoring genomic 
feature to be a deletion on chromosomal locus chr5q21.3 (Fig. 4.5A), harboring tyrosine 
kinase receptor-encoding gene EFNA5. EFNA5, a member of the Eph receptor family, 
has been hypothesized to function as a tumor suppressor, whose expression has been 
shown to be reduced in human BRCAs relative to normal epithelial tissue(Fu et al., 
2010). Advancing to a second iteration, CaDrA then identified an additional deletion of 
chr20p13 as the next-best feature (Fig. 4.5A). chr20p13 includes multiple genes (Table 
4.4), including RBCK1, whose reduced expression has been shown to be associated with 
increased tumor cell proliferation and survival, as well as with worse patient survival 
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outcomes in breast cancer (Donley et al., 2014). CaDrA then proceeded to identify 
somatic mutations in the RELN gene, before terminating the search process (P ≤ 0.001; 
Fig. 4.5A). Loss of RELN expression has indeed been shown to induce cell migration in 
esophageal carcinoma, and to be associated with poor prognosis in breast cancer (Stein et 
al., 2010; Yuan, Chen, Ma, Cao, & Liu, 2012). To ensure that the derived meta-feature 
association is not a spurious consequence of correlation with tumor subtype, we tested for 
the association of YAP/TAZ activity and this derived meta-feature while controlling for 
BRCA triple negative (TN) status. The results confirmed that the positive association 
between YAP/TAZ activity and the occurrence of these genomic alterations is 
independent of BRCA patho-histology (Fig. S.5). Analysis of YAP/TAZ activity based 
on the same knockdown signature in CCLE BRCA cell lines (n=59; Fig. S.6A) shows 
that RBCK1 and RELN display the highest anti-correlation between their gene expression 
and YAP/TAZ activity (Fig. S.6B). In order to assess whether these identified candidates 
indeed drive the elevated YAP/TAZ activity phenotype, we performed siRNA-mediated 
knockdown of RELN or RBCK1 in HS578T breast cancer cells, followed by expression 
quantification of YAP/TAZ canonical targets, which serves as a read-out of nuclear 
YAP/TAZ activity (Piccolo, Dupont, & Cordenonsi, 2014). HS578T cells, similar to 
MDA-MB-231 cells from which the gene signature was derived, are triple negative 
BRCA cells but display lower overall YAP/TAZ activity (rank 7/59) compared to the 
latter (rank 54/59). Importantly, knockdown of either of these candidate drivers in these 
cells yielded a significant increase (FDR < 0.05; two-tailed Student’s t-test) in expression 
levels of YAP/TAZ targets CTGF and CYR61, validating the association of their loss of 
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function with increased YAP/TAZ transcriptional activity (Fig. 4.5B). In summary, 
unbiased application of CaDrA to the analysis of oncogenic YAP/TAZ activity in 
primary BRCA samples identified multiple novel candidate drivers of that activity, and 
our experimental in vitro validation confirmed the causal role of the top two candidates, 
RBCK1 and RELN, in that activity, thus confirming the ability of our tool to discover 
novel drivers. 
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4.4 Discussion 
Identifying (epi)genetic drivers of molecular readouts is of fundamental 
importance to determining alternative mechanisms influencing the phenotype in question. 
Existing methods attempting to extract functionally-relevant sets of genomic alterations 
associated with a given context either do not support the analysis of data beyond somatic 
mutations, do not incorporate multiple feature scoring functions and search modes, or do 
not implement rigorous statistical significance testing of the obtained results. Importantly, 
a computational framework package bundling all of these features does not exist, and can 
significantly help identify novel drivers of signature activity. 
Here, I presented CaDrA as a tool that determines a subset of queried binary 
features to be most-associated with a phenotypic signature of interest by specifically 
exploiting a stepwise heuristic search method based on their union. CaDrA was applied to 
identify both known and novel genomic drivers of sample signature activity, comprising 
drug sensitivity and gene set activity estimates, using publically available datasets 
pertaining to cancer cell lines and primary tumors. Querying CCLE data for features 
associated with increased sensitivity to Mek/Raf inhibitors, CaDra recovered known 
driver mutations in oncogenes known to be gate-keepers of MEK pathway activity, 
including NRAS and BRAF.  
Through the extensive evaluation on simulated data, I was able to highlight 
CaDrA’s high sensitivity and specificity for mid-to-large sized datasets (N > 100). 
Importantly, multi-omic datasets produced by networks such as CCLE and TCGA, also 
presented in this study, are well above this sample size limit. CaDrA’s specificity was 
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further evident when querying genetic drivers of increased sensitivity to treatment with 
PLX4720, a potent and selective inhibitor designed to preferentially inhibit active B-Raf 
protein bearing the V600E allele (J. Tsai et al., 2008). In this scenario, the search process 
correctly identified the BRAFV600E mutation as the sole feature associated with elevated 
sensitivity to treatment, in agreement with the known specificity of the small molecule 
inhibitor, with the feature association being highly statistically significant.  Importantly, I 
was able to demonstrate the utility of this new framework in the discovery of novel 
drivers in human breast cancers. Specifically, I asked whether there were genomic 
alterations associated with elevated activity of Hippo pathway co-activators YAP/TAZ 
known to control pro-tumorigenic signals in multiple cancer types (Hiemer et al., 2015; 
Moroishi et al., 2015; Zanconato et al., 2016). The mechanisms contributing to 
dysregulated YAP/TAZ activity in cancer are poorly understood. To date, very few 
genomic alterations have been associated with driving tumorigenic YAP/TAZ activity 
(Harvey et al., 2013). Projecting TCGA human BRCA RNASeq data onto a YAP/TAZ-
regulated gene expression signature, I derived per-sample estimates of YAP/TAZ activity 
which was then used as the input ranking variable to CaDrA. CaDrA identified 
chromosomal deletions of 5q21.3 and 20p13, and mutations in the RELN gene as 
maximally-associated with elevated YAP/TAZ activity based on the union of their 
occurrences in TCGA samples. Analysis of this identified meta-feature with respect to 
BRCA TN status confirmed that these genomic alterations are significantly associated 
with YAP/TAZ activity independent of sample clinical subtype. We wished to validate 
whether introduction of these identified perturbations would drive a cell towards higher 
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YAP/TAZ activity, in turn, pheno-copying the observed trend in primary BRCAs. 
Knockdown of select targets, namely RELN and RBCK1, in HS578T BRCA cells 
exhibiting low YAP/TAZ-activity resulted in a significant increase in the expression of 
canonical YAP/TAZ targets CTGF and CYR61, confirming their involvement in the 
regulation of YAP/TAZ-mediated activity. Since CaDrA was designed to identify 
genomic alterations impacting similar events, I believe these results to further emphasize 
its use as a valuable tool in identifying and linking novel signaling effectors with a target 
outcome of interest.  
While the analyses presented focused on somatic mutations and SCNAs, we 
believe CaDrA’s search functionality can be applied to additional sequencing readouts, 
including and not limited to, DNA methylation and microRNA expression, albeit with 
proper discretization of these continuous features. A joint analysis of these additional 
data types might provide insight into epigenetic mechanisms that complement the 
assessed genetic features in driving phenotypic variation. Furthermore, I envision the 
adoption of CaDrA for the study of germ-line variation as well, thus contributing to move 
beyond the “one feature at a time” paradigm typical of GWAS studies, although issues of 
computational efficiency in that problem space will likely become more challenging. 
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4.5 Conclusion 
Here, I presented Candidate Driver Analysis (CaDrA), a methodology that 
searches for the set of genomic alterations associated with a user-provided ranking of 
samples. This framework, distinct from previously reported methods, employs a stepwise 
heuristic search to identify a subset of features whose union is maximally-associated with 
the observed sample ranking, while also carrying out rigorous statistical significance 
testing based on sample permutation. To highlight the method’s overall performance, 
along with its relevance and ability to select sets of genomic features that indeed drive 
certain oncogenic phenotypes in cancer, I applied CaDrA to simulated data, as well as to 
real genomic data corresponding to cancer cell lines and patient tumor cohorts. The 
results of simulation suggested CaDrA displays high sensitivity and specificity for mid- 
to large-sized datasets. Using genomic data drawn from CCLE and TCGA, I 
demonstrated CaDrA’s capacity to correctly identify well-characterized driver mutations 
in cell lines, along with its ability to discover less-known features associated with 
invasive phenotypes in human tumors, which was further functionally validated in vitro. 
The CaDrA package, which is publicly-available, will allow for rapidly mining numerous 
datasets for candidate drivers of user-specified molecular readouts, including, but not 
limited to, pathway activity or drug sensitivity estimates, and gene/protein expression 
levels. Given the rapid rise in the availability of multi-omics datasets, as well as an 
increased need to interrogate targeted molecular readouts within these contexts, we 
believe that our methodology will accelerate feature prioritization for further follow-up 
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and consideration, in turn aiding in the discovery of potential drivers of the outcome of 
interest. 
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Table 4.1 Sensitivity of CaDrA based on simulated data  
Summary of overall true positive rate (TPR) of CaDrA on simulated data for different sample sizes. Percentages are 
weight-averaged over TPRs corresponding to different number of true positive features per meta-feature, weighted by 
the total searches returning such meta-features (see Fig. 4.2B). 
 
Sample Size 
(N) 
Mean TPR 
(%) 
Std dev. TPR 
(%) 
50 7.69 3.85 
100 96.51 12.06 
250 100 - 
500 100 - 
 
 
Table 4.2 Specificity of CaDrA based on simulated data 
Summary of overall false positive rate (FPR) of CaDrA on simulated data for different sample sizes. Percentages are 
weight-averaged over FPRs corresponding to different meta-feature sizes, weighted by the total searches returning such 
meta-features (see Fig. 4.2D). 
 
Sample Size 
(N) 
Mean FPR 
(%) 
Std dev. FPR 
(%) 
50 7.2 3.8 
100 4.6 2.77 
250 4.6 1.94 
500 4.2 1.43 
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Table 4.3 Mutation sets associated with elevated sensitivity to Mek and Raf inhibition in cancer cell lines  
Mutations in genes identified by CaDrA as associated with increased sensitivity to inhibitors targeting Mek (AZD6244, 
PD-0325901) and Raf (PLX4720) are shown, along with the corresponding permutation p-value of each search result. 
 
Target Treatment CaDrA hits P-value 
MEK AZD6244 BRAF.V600E, NRAS, APAF1, TGFBR2, AMHR2 0.001 
MEK PD-0325901 BRAF.V600E, NRAS, TRIM33 0.001 
RAF PLX4720 BRAF.V600E 0.001 
RAF RAF265 TTK, BRAF.V600E, ZMYM2, IL21R, BCL11B, MAP3K5, TAF15 0.005 
 
 
 
 
Table 4.4 Genomic alterations associated with elevated YAP/TAZ activity in TCGA BRCAs  
CaDrA identified two genomic deletions and a mutation in RELN as associated with increased oncogenic YAP/TAZ 
activity in BRCA samples from TCGA. Also shown are genes within each of the identified chromosomal deletion 
peaks 
 
CaDrA 
hits 
Genes in region P-value 
Del5q21.3 RN7SL782P, SNORA31, EFNA5  
 
0.001 
Del20p13 TCF15, CSNK2A1, SOX12, RBCK1, TRIB3, NRSN2, ZCCHC3, SCRT2, 
SLC52A3, TBC1D20, C20orf96, SRXN1, DEFB125, DEFB126, DEFB127, 
DEFB128, DEFB129, DEFB132 
RELN N/A 
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Illustration 4.1 Simulated data generation for the evaluation of CaDrA performance  
Schematic representation of a simulated data used for CaDrA performance evaluation, along with parameters used for 
data generation. A typical binary matrix highlighting the nature of the left-skewed (positive) features and the uniformly 
distributed (null) features is shown. CaDrA was run on datasets with either only null features, or with both positive and 
null features in order to determine specificity and sensitivity estimates, respectively. 
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Figure 4.1 Overview of CaDrA workflow and implementation  
CaDrA takes as input a sample-specific measurement to determine sample ranks along with a binary feature matrix for 
the same sample set. In Step 1 (blue box), CaDrA begins by choosing a starting feature, which is either the single 
feature having the best score based on the left-skewdness of its events, or a user-specified start feature. In the next step 
(Step 2; orange box), the union (logical OR) of this feature is taken with each of the remaining features in the dataset, 
yielding ‘meta-features’ with their corresponding scores. If any meta-feature has a better score than the hit from the 
previous step (Step 3; green box), CaDrA uses this new meta-feature as a reference for the next iteration, reiterating 
over Steps 2 and 3 until no further improvement in scores can be obtained. The final output is a set of features (meta-
feature) whose union has the (local) maximal score.  
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Figure 4.2 Performance evaluation of CaDrA using simulated data 
CaDrA was run on 500 independent simulated datasets containing both positive and null (A, B) and only null (C, D) 
features with different sample sizes (gray box above each sub-panel). In each case, the distribution of the number of 
features per meta-feature (i.e. the meta-feature size) returned by CaDrA is shown (A, C) as well as the corresponding 
number and fraction of searches that yielded significance for =0.05 (B, D). For example, panel A shows that for 
datasets of size 100, about 375 of the 500 runs returned meta-features of size 5 (i.e., containing 5 features), and in 350 
of those runs all five features were true positive (dark blue portion of the bar plot). At sample sizes of 250 and 500, all 
returned meta-features were of size 5 and all true positives, with statistically significant permutation p-values yielding 
100% sensitivity, as indicated in panel b. Panel C shows CaDrA returned meta-features of varying sizes, with majority 
of these not statistically significant for the  level considered, as indicated in panel D. 
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Figure 4.3 CaDrA identifies mutations in MAPK/ErK signaling genes that contribute to hyper-sensitivity to 
MEK inhibition in vitro  
ActArea measurements reflecting sensitivity to MEK inhibitor AZD6244 were used for rank CCLE cell lines (n=477). 
CaDrA was then run to identify sets of genomic features that were most-associated with elevated ActArea (i.e. 
increased sensitivity) scores. Through step-wise search iterations, CaDrA identified somatic mutations in known 
regulators upstream of MEK, including an activating mutation in BRAF (BRAFV600E) and NRAS, as well as those in 
APAF1, TGFBR2 and AMHR2, before terminating the search process. The resulting meta-feature (red track) and its 
corresponding enrichment score (ES) is shown. 
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Figure 4.4 CaDrA hits associated with elevated sensitivity to inhibitors of MEK and Raf in cancer cell lines 
CaDrA was run using ActArea drug sensitivity measurements pertaining to AZD6244 (A), PD-0325901 (B), PLX4720 
(C) and RAF265 (D) treatment as a sample ranking variable, and somatic mutation and copy number alteration data as 
binary features from CCLE. The top hits (meta-feature) identified in each case are shown (also summarized in Table 
4.3). 
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Figure 4.5 CaDrA identifies novel drivers of oncogenic YAP/TAZ activity in human breast carcinomas 
A. TCGA BRCA RNASeq data (n=951) was projected in the space of a gene signature comprising YAP/TAZ-
activating genes to yield a sample stratification based on YAP/TAZ activity estimates (blue area plot; see Methods). 
CaDrA was then run to look for features associated with elevated YAP/TAZ activity, returning two chromosomal 
deletions (Del5q21.3, Del20p13), and a somatic mutation in RELN (black tracks). The union of the three features (red 
track) and the corresponding running enrichment score (ES) is also shown. B. siRNA-mediated transcriptional 
knockdown of 20p13-harboring gene RBCK1, and RELN in HS578T cells resulted in a significant increase in the 
expression of TAZ and canonical YAP/TAZ targets CTGF and CYR61, as indicated by their relative qRT-PCR 
expression, confirming the identified CaDrA hits as potential regulators of BRCA-associated YAP/TAZ activity. Ctrl: 
Scrambled control; YT: YAP/TAZ; * FDR < 0.05; ** FDR < 0.01; two-tailed unpaired Student’s t-test. 
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CHAPTER FIVE:  General Conclusions and Future directions 
HNSCC might only account for 3-5 % of global cancer cases, yet it continues to 
be a serious burden to human health, characterized by aggressive molecular phenotypes 
concomitant with poor patient outcomes. It is indeed remarkable to see the medical 
community make numerous advancements in recent years related to surgical 
interventions for HNSCC, including the use of improved robotics technology in the 
removal of harmful malignant tissue that is typically difficult to access. While this helps 
deal with urgent care and intervention of aggressive disease, it does not make up for the 
lack of reliable therapeutics capable of targeting underlying molecular cues in order to 
abrogate the invasiveness of HNSCC. The complex genetic and genomic landscape of 
these clinically and biologically-heterogeneous cancers is slowly beginning to be 
unveiled through large inter-disciplinary investigations.  
 In this dissertation, I presented a series of studies that exploited the interrogation 
of large high-throughput cancer genomic datasets, combined with experimental methods 
for molecular profiling, signature generation, and functional validation using cellular and 
animal models in order to highlight different molecular features that are associated with 
the onset and progression of HNSCs. Importantly, I further stress the need for novel 
computational methods capable of leveraging these data to elucidate genomic anomalies 
driving pro-tumorigenic activity.     
  The results from the previous chapters contend that: 
- Safe and selective inhibition of abnormal -catenin activity in HNSCCs is possible 
through specific targeting of the interaction between -catenin and one of its binding 
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co-activators, CBP, in the nucleus. This was demonstrated using a preclinical 
molecule ICG-001, the therapeutic potential of which has been previously explored 
in other biological contexts, but hasn’t been evaluated for HNSCCs. Importantly, I 
highlight how potent inhibition of the aforementioned activity has clinical relevance 
for both diagnosis and prognosis in human OSCCs, further suggesting -catenin/CBP 
signaling activity as an important target for further mechanistic investigation and 
clinical management.  
- Average gene expression of the three major collagens produced by fibroblast cells 
serves as a surrogate marker of fibroblast activity, and can be used towards the 
identification of CAF markers in human cancers of multiple tissue types. 
Importantly, applying this unbiased collagen-based co-expression analyses revealed 
PDGFR, which we later validated to be a robust, CAF-specific marker in OSCC. 
- A stepwise heuristic search framework supports the selection of functionally and 
clinically-relevant subsets of (epi)-genetic drivers of oncogenic activity using multi-
omic data. Of relevance, I developed this framework as a flexible, publicly-available 
R package, and demonstrate its ability to recover both know, as well as novel drivers 
in cancer cell lines and human tumors, respectively, with functional validation of the 
latter. 
While this body of work has collectively identified important markers associated 
with aggressive HNSCC, and further highlights the promise of utilizing publicly available 
datasets and novel algorithms for the purpose of data integration and targeted queries, it 
merely scratches the surface in disentangling the complex network of molecular factors 
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implicated in these malignancies. Several follow up experiments and analyses can 
provide additional evidence to these findings, and may help us gain new insight into the 
less-understood mechanisms that might be implicated thereof. 
While we demonstrated the therapeutic potential of ICG-001 via the inhibition of 
-catenin/CBP activity, this remains purely a pre-clinical, limited by the lack of solubility 
exhibited by this molecule. Third-generation derivatives of ICG-001 that are water-
soluble, and hence, capable of being orally administered during treatment are now being 
implemented in clinical trials for other cancers, and thus show immense potential for the 
treatment of HNSCC as well, which our ongoing studies aim to confirm at the molecular 
level. 
One can hypothesize that targeting these CAFs, in addition to transformed 
epithelial cells, will only complement desired anti-tumorigenic activity by restricting 
microenvironment-driven cancer dependencies. Here, we identified several candidate 
CAF markers, including PDGFR, to be associated with progression and fibroblast-
specificity in human HNSCCs. Indeed, multiple antagonists of PDGFR exist, yet the use 
of these in combination with standard therapeutics of HNSCCs is yet to be explored, and 
can improve our understanding of the complex interplay between the tumor and its 
dynamic cellular microenvironment.   
In the analyses of candidate drivers of oncogenic activity using the CaDrA 
framework, I only queried genetic alterations as a proof-of-concept. Adding in other 
layers of genomic information, specifically those that capture epigenetic mechanisms 
such as DNA methylation and microRNA expression, might help explain why certain 
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samples exhibit elevated pathogenic activity, while lacking any of the queried genetic 
anomalies. Importantly, there is virtually no limit to the number of signatures one can use 
to query these genomic datasets across contexts, making CaDrA even more exploitable. 
Further, there is the possibility of extending this stepwise search approach to genome-
wide association studies (GWAS) data, allowing one to move away from analyzing 
individual single nucleotide polymorphisms (SNPs) at a time, but the computational scale 
of this problem will need to be carefully evaluated. Additionally, the incorporation of 
feature scoring functions such as mutual information criterion, implemented in the 
REVEALER algorithm(J. W. Kim et al., 2016), will enable one to specifically look for 
features that are mutually exclusive with each other, while also being correlated with the 
target profile of interest. Indeed, the incorporation of such scoring functions will only 
benefit from the statistical significance estimation module built into CaDrA, which 
REVEALER lacks. 
Taken together, these studies identified important pathobiological drivers of 
HNSCC progression through the application of computational genomic approaches, and 
further expose the immense benefits of utilizing large multi-omic data and new search 
frameworks that enable mechanistic inquiries and novel hypothesis generation. 
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APPENDIX 
 
Figure S.1 TOPflash assay confirming the inhibitory impact of ICG-001 on -catenin-mediated transcriptional 
activity in HSC-3 cells  
HSC-3 cells were treated with either no (DMSO vehicle) or 10 µM ICG-001 for 48 hours, following which luciferase 
activity was determined. TOP/FOPflash activity was expressed relative to the transfection control as relative luciferase 
units (RLUs). Relative luciferase activity is displayed as mean + S.D RLUs (n=3). * P < 0.005 two-tailed unpaired 
Student’s t-test. 
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Figure S.2 Immunostaining of  smooth muscle actin (SMA) in oral tongue tissue  
Immunohistochemistry showing expression of well-known CAF marker SMA in adjacent normal oral epithelium, 
hyperplasia, ulcer and OSCC specimens. Staining indicates that, while SMA expression correlates with progression, it 
is not expressed in fibroblasts as exclusively as PDGFR 
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Figure S.3 Immunostaining of podoplanin in oral tongue tissue  
Immunohistochemistry showing expression of well-known CAF marker podoplanin in adjacent normal oral epithelium, 
hyperplasia, ulcer and OSCC specimens. Staining indicates that, while podoplanin expression correlates with 
progression, it is not expressed in fibroblasts as exclusively as PDGFR 
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Figure S.4 P-value distributions for CaDrA runs on simulated datasets 
Distribution of permutation p-values returned by CaDrA for searches performed on true positive (A) or null (B) 
simulated datasets of different sample size ranges (N = 50,100,250 or 500) for n = 500 runs per sample size group is 
shown. Searches on null datasets that lack skewed binary features are uniformly distributed, independent of sample 
size. 
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Figure S.5 CaDrA identifies alterations associated with YAP/TAZ activity independent of tumor subtype in 
TCGA BRCA 
Shown is a box plot of derived YAP/TAZ activity estimates in TCGA BRCA samples for triple negative (TN) and non-
TN samples. Sample groups are further stratified by the presence or absence of the union alteration status of the meta-
feature identified by CaDrA (Fig. 4.5A). Linear regression of the YAP/TAZ activity modeled as a function of the 
sample TN and union alteration status confirmed that YAP/TAZ activity is significantly associated with the meta-
feature occurrence independent TN status (linear regression P < 0.0001), as also evident in the boxplot shown. 
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Figure S.6 Interrogation of CaDrA hits associated with increased TCGA BRCA YAP/TAZ activity in CCLE 
BRCA cell lines  
A. Projection of CCLE BRCA cells (n=59) in the space of MDA-MB-231-derived YAP/TAZ-activating genes yielding 
activity scores per cell line (purple area plot) B. Correlation of the derived YAP/TAZ activity scores with expression 
levels of genes identified by CaDrA to be associated with elevated YAP/TAZ activity (Table 4.4). RELN and RBCK1 
show relatively higher anti-correlation between YAP/TAZ activity and their mRNA expression levels, and were 
selected for knockdown and qRT-PCR validation in vitro. Only genes with expression profiles in CCLE are shown.  
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